

M. Roy Wilson, M.D., M.S.

*Deputy Director, Strategic Scientific Planning and Program Coordination
National Institute on Minority Health and Health Disparities, National Institutes of Health*

Chancellor Emeritus, University of Colorado Denver

Phone: 301-402-0050
E-mail: mroy.wilson@nih.gov
Address: 4720 Rosedale Ave. #407
Bethesda, MD 20814
Date of Birth: November 28, 1953
Place of Birth: Yokohama, Japan
Citizenship: U.S.A.

Education

1976 B.S. Allegheny College
Meadville, Pennsylvania
1980 M.D. Harvard Medical School
Boston, Massachusetts
1990 M.S. (Epidemiology) School of Public Health, UCLA
Los Angeles, California

Postdoctoral Training

Internship: Internal Medicine
1980-1981 Harlem Hospital Center
New York, New York
Residency: Ophthalmology
1981-1984 Massachusetts Eye & Ear Infirmary
Harvard Medical School
Fellowship: Glaucoma
1984-1985 Massachusetts Eye & Ear Infirmary
Harvard Medical School

Licensure and Certification

1981 Diplomat, National Board of Medicine 226339
1984-2004 Massachusetts Licensure, No. 52507
1986-2005 California License, No. G57562
1986 Diplomat, American Board of Ophthalmology
1998-2004 Nebraska License, No. 20983

2003-2006 Texas License, Provisional License for Distinguished University Professors

2007-Current Colorado License, No. 45762

Certificate Programs

1996 (Executive Management) Anderson School of Management, UCLA
Los Angeles, California

1997 (Executive Development) Marshall School of Business, USC
Los Angeles, California

Administrative Leadership Positions

1986-1994 Chair
Department of Ophthalmology, College of Medicine
Charles R. Drew University of Medicine and Science
Los Angeles, California

1993-1998 Dean
College of Medicine
Charles R. Drew University of Medicine and Science

1997-1998 Associate Dean
School of Medicine
University of California, Los Angeles
Los Angeles, California

1998-2003 Dean
School of Medicine
Creighton University
Omaha, Nebraska

1999-2001 Interim Vice President for Health Sciences
Creighton University

2001-2003 Vice President for Health Sciences
Creighton University

2003-2006 President
Texas Tech University Health Sciences Center
Lubbock, Texas

2006-2010 Chancellor
University of Colorado Denver (formerly two separately
accredited institutions: University of Colorado at Denver and
University of Colorado Health Sciences Center)
Denver and Aurora, Colorado

2010-Current Chancellor Emeritus
University of Colorado Denver

2010-2011 Acting President/CEO
Charles R. Drew University of Medicine and Science

Jan 2012-Current Deputy Director, Strategic Scientific Planning and Program
Coordination
National Institute on Minority Health and Health Disparities,
National Institutes of Health

Academic Appointments

1985-1986 Clinical Assistant in Ophthalmology
Harvard Medical School

1986-1990 Assistant Professor, Department of Ophthalmology
Charles R. Drew University of Medicine and Science

1986-1991 Assistant Professor, Department of Ophthalmology
University of California, Los Angeles

1990-1994 Associate Professor, Department of Ophthalmology
Charles R. Drew University of Medicine and Science

1991-1994 Associate Professor, Department of Ophthalmology
University of California, Los Angeles

1994-1998 Professor, Department of Ophthalmology
Charles R. Drew University of Medicine and Science

1994-1998 Professor, Department of Ophthalmology
University of California, Los Angeles

1998-2003 Professor, Department of Surgery
Creighton University

2003-2006 Professor, Department of Ophthalmology
Texas Tech University Health Sciences Center

2006-2010 Professor, Department of Ophthalmology
University of Colorado Denver

Hospital Appointments

1985-1986 Assistant in Ophthalmology
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts

1985-1986 Consultant Ophthalmologist
Victoria Hospital

Castries, St. Lucia (West Indies)

1986-1998
UCLA Hospital
Los Angeles, California

1986-1998
Chief Physician
King/Drew Medical Center
Los Angeles, California

1998-2003
Creighton University Medical Center
Omaha, Nebraska

2003-2006
University Medical Center
Lubbock, Texas

2006-2011
University of Colorado Hospital
Aurora, Colorado

2012-Current
NIH Clinical Center
Bethesda, Maryland

Other Appointments

1985-1986
Project Director
International Eye Foundation
Ministry of Health
Castries, St. Lucia

2010-2011
Senior Scholar
Association of Academic Health Centers (AAHC)
Washington, DC

2010-2011
Counselor, Association of Public and Land Grant Universities
Washington, DC

Awards and Honors

1973,1974,1975,1976
Alden Scholar, Allegheny College

1976
Phi Beta Kappa, Allegheny College

1976
Magna Cum Laude, Allegheny College

1976
Department Honors in Biology, Allegheny College

1976
Senior Thesis Award, Allegheny College

1990
Personal Dedication Award, Department of Ophthalmology,
King/Drew Medical Center

1993
Honor Award, American Academy of Ophthalmology

1994	Honored Alumnus Award, Massachusetts Eye and Ear Infirmary
1995	Distinguished Physician Award, Minority Health Institute
1996	Best Doctors in America multiple consecutive year listing from 1996-2007, 2009-2010
2000	Alpha Omega Alpha, Faculty Member
2000	Research Centers in Minority Institutions (RCMI) Award of Excellence, Charles Drew University of Medicine and Science
2001	Outstanding Service Award, Creighton University School of Medicine, Class of 2001
2001	Top Cat Award, Nebraska Chapter of American Academy of Pediatrics
2002	Dr. Stan Truelsen Award, Prevent Blindness Nebraska
2002	2 nd Annual Award, Roman Barnes Society of Ophthalmology
2003	Admiral, Great Navy of the State of Nebraska
2003	Senior Achievement Award, American Academy of Ophthalmology
2003	Gold Citation, Allegheny College
2004	Headliner Award, Women in Communications
2007	Herbert W. Nickens Award, American Association of Medical Colleges
2008	Golden Key International Honor Society, Honorary Member
2009	Community Star Award, Northeast Academy Charter School
2011	Finalist, Healthcare CEO of the Year Los Angeles Business Journal

Governing Board Memberships

1998-2001	Boys and Girls Club of Omaha Omaha, Nebraska
1998-2003	Creighton University Medical Center (CUMC) Omaha, Nebraska
1998-2003	Children's Physicians

(Creighton's Pediatric Faculty Practice Plan with Children's Hospital)
Omaha, Nebraska

1998-2003 Glaucoma Foundation
New York, New York

1998-2003 Treasurer, UniNet Healthcare Network
(Physician Hospital Organization with CUMC and Alegent Health System)
Omaha, Nebraska

1998-2003 Creighton – Nebraska Universities Health Foundation
(President, 2001- 2002)
Omaha, Nebraska

1998-2003 Chairman, Creighton Medical Associates (Faculty Practice Plan)
Omaha, Nebraska

2001-2003 Treasurer, Creighton University-BoysTown Healthcare Foundation
Omaha, Nebraska

2002-2003 International Latin American Concern
Santiago, Dominican Republic

2003-2005 Prevent Blindness Texas
Lubbock, Texas

2003-2005 Reese Redevelopment Authority Board
Lubbock, Texas

2004-2006 United Way
Lubbock, Texas

2006-2010 Chairman, University of Colorado Hospital
Aurora, Colorado

2006-2010 The Children's Hospital
Aurora, Colorado

2006-2010 Auraria Higher Education Center
Denver, Colorado

2006-2010 Fitzsimons Redevelopment Authority
Aurora, Colorado

2006-2010 AMC Cancer Research Center
Denver, Colorado

2006-2010 University of Colorado Foundation

	Denver, Colorado
2007-2009	Institute of International Education Rocky Mountain Region Denver, Colorado
2007-2009	Colorado Biosciences Association Denver, Colorado
2007-2010	Delta Eta Boule Foundation Denver, Colorado
2008-2011	Coalition of Urban Serving Universities Washington, DC
2008-2011	Association of Academic Health Centers Washington, DC
2008-2011	Institute for the Advancement of Multicultural & Minority Medicine Washington, DC
2008-Current	American International Health Alliance, Inc. Washington, DC
2009-2010	Global Down Syndrome Foundation Denver, Colorado
2009-2011	Association of Public and Land Grant Universities Washington, DC
Sept 2010-Jan 2012	Chairman, Charles R. Drew University of Medicine and Science

Professional Societies (by invitation)

2002-Current	American Ophthalmological Society (by invitation and acceptance of thesis)
2003-Current	International Glaucoma Research Society (membership limited to 75 worldwide)
2003-Current	Institute of Medicine, National Academy of Sciences

Other Professional Societies

1979-1985	Massachusetts Medical Society
1979-2009	American Medical Association
1980-Current	Harvard Medical Alumni Association

1981-1984	National Association of Interns & Residents
1983-1989	Trabecular Meshwork Study Club
1984- Current	Association for Research in Vision and Ophthalmology
1984-Current	Chandler-Grant Glaucoma Society
1985-Current	National Medical Association
1985-Current	American Academy of Ophthalmology
1985-1990	Society of Eye Surgeons International Eye Foundation
1985-Current	Massachusetts Eye and Ear Infirmary Alumni Association
1986-1998	Southern California Glaucoma Society
1986-1998	West Coast Glaucoma Study Club
1986-1993	Association of University Professors in Ophthalmology
1987-Current	UCLA Department of Ophthalmology Alumni Association
1988-1998	Los Angeles County Medical Association
1988-1998	Los Angeles Society of Ophthalmology
1988-1998	California Medical Association
1989-Current	American Glaucoma Society
1992-2000	Society for Epidemiologic Research
1992-2000	American Public Health Association
1997-2000	American College of Epidemiology
1998-2003	Executive Committee, Metro Omaha Medical Society
1998-2003	Omaha Ophthalmologic Society
1999-2003	Nebraska Academy of Ophthalmology
1999-2005	Association of Academic Minority Physicians
1998-2005	Pan American Association of Ophthalmology
2003-2006	Texas Medical Association

2003-2006 Academy of Medicine, Engineering, and Science of Texas

Federal Committees/Advisories

1994-2009 Executive/Steering Committee,
NEI (NIH) Ocular Hypertension Treatment Study Clinical Trial

1995-1999 FDA Advisory Committee, Dermatologic and Ophthalmic Drugs

2000-2001 National Research Council, Committee on Disability
Determination for Individuals with Visual Impairments

2000-2002 Advisory Committee, Office of Minority Health, NIH

2001-2008 FDA Advisory Committee, Ophthalmic Devices Panel

2002 NSF Advisory Panel, Survey of Scientific and Engineering
Research Facilities, National Science Foundation

2002-2005 Advisory Council, National Center on Minority Health and Health
Disparities, NIH

2003-2005 Chair, Strategic Plan Subcommittee
National Center on Minority Health and Health Disparities,
NIH

2006-2010 Advisory Council, National Center for Research Resources, NIH

2010-Current Chair, NIH Data Monitoring and Oversight Committee
Los Angeles Latino Eye Study III, National Eye Institute

2011-2012 National Advisory Committee to the NIH Director, Diversity of
Biomedical Research Workforce

2012 FDA Advisory Committee, Dermatologic and Ophthalmic Drugs

2013- Co-chair, NIH Common Fund Initiative on Diversity of
Biomedical Research Workforce

Other Major National Committees and Advisories

1990-1994 National Scientific Advisory Board, Diabetes 2000
American Academy of Ophthalmology

1992-2000 National Scientific Advisory Board for Glaucoma 2001
American Academy of Ophthalmology

1994-1995 Chair, ARVO Task Force on Minority and Women Issues
Association for Research in Vision and Ophthalmology

2000-2010 National Advisory Board, EyeCare America, Glaucoma Project

	American Academy of Ophthalmology
2002-2003	Institute of Medicine, Committee on Roles of Academic Health Centers in the 21 st Century
2008-2011	Presidential Chair, Urban Health Initiative Coalition of Urban Serving Universities
2009-2011	Chair, Commission on Access, Diversity, and Excellence Association of Public and Land-Grant Universities
2009-Current	Chair, Advisory Board, Hoskins Center for Quality Eyecare, American Academy of Ophthalmology
2010-2011	Institute of Medicine Committee on Geographic Adjustment Factors in Medicare Payment (Phase I)
2011-2012	Vice-Chairman, Institute of Medicine Committee on Geographic Adjustment Factors in Medicare Payment (Phase II)
2012-Current	National Advisory Committee, Robert Wood Johnson Foundation

Editorial Boards

1994-2000	Section Editor, Glaucoma Update Section Journal of Glaucoma
1994-2002	Member, Focus on Glaucoma
1999-Current	Member, Archives of Ophthalmology

Review Activities

1988-Current	Reviewer, Peer Review Journals Journal of Glaucoma Ophthalmology Investigative Ophthalmology and Visual Science American Journal of Ophthalmology Journal of American Medical Association Archives of Ophthalmology Survey of Ophthalmology British Journal of Ophthalmology
1990	Special Review Committee SRC-O2 National Eye Institute, NIH
1991	Ad Hoc Reviewer Visual Sciences A2 Study Section National Eye Institute, NIH Committee Member, Ad Hoc Site Visit

National Institute on Aging, NIH

1992-1996 Vision Research Review Committee
National Eye Institute, NIH

1992 Committee Member, Ad Hoc Grant Review
British Columbia Health Research Foundation

Committee Member, Ad Hoc Grant Review
National Institute on Aging, NIH

1993 Special Review Committee for Foreign Grant Applications
National Eye Institute, NIH

1995 Committee Member, Ad Hoc Grant Review
Hong Kong Research Committee

1996-2000 Clinical Research Review Committee
National Eye Institute, NIH

2008-2012 Asia Pacific Glaucoma Guideline International Review
Committee

2011 Special Emphasis Panel: R25 Applications
National Institute on Minority Health and Health Disparities,
NIH

2011 Special Emphasis Panel: U24 Applications
National Institute on Minority Health and Health Disparities,
NIH

2013 Federal Selection Panel (2nd level review): Audacious Goals
Initiative
National Eye Institute, NIH

Other Professional Activities

1987 Faculty of Academy-Sponsored Skills Transfer Course:
Laser Lab: *Laser Applications in Glaucoma*
American Academy of Ophthalmology
Courses HO-303, HO-337, and HO-347
Dallas, Texas

1987-1988 Regional Chairman, Ophthalmology Section
National Medical Association

1987-1988 Chair, Glaucoma Section
National Medical Association

1987-1990 Advisor
International Eye Foundation

Bethesda, Maryland

1988 Program Chair, Pre-Convention Scientific Symposia: *Glaucoma and Intraocular Lens*
National Medical Association
Los Angeles, California

Faculty of Academy-Sponsored Skills Transfer Course:
Laser Lab: *Laser Applications in Glaucoma*.
American Academy of Ophthalmology
Courses H0-310, H0-342, and H0-369
Las Vegas, Nevada

1989 Faculty of Academy-Sponsored Skills Transfer Course:
Laser Lab: *Laser Applications in Glaucoma*
American Academy of Ophthalmology
Courses H0-113, H0-146, and H0-171
New Orleans, Louisiana

1989-1996 Great Hands Advisory Board
Beaver Instruments, Becton Davidson

1990 Glaucoma Faculty for Project Orbis
Cameroon, Africa

Moderator, Clinical Research:
Glaucoma/Vision Research Section
Association for Research in Vision and Ophthalmology
Sarasota, Florida

1990-1996 Research and Development Committee
Singapore Association of the Visually Handicapped

1990-1997 Faculty Advisory Board; Merck, Sharpe, and Dohme

1991 Facilitator, First Cameroon Symposium on Blindness and
Visual Impairment
Maroua, Cameroon, Africa

Moderator, Clinical Research:
Glaucoma/Vision Research Section
Association for Research in Vision and Ophthalmology
Sarasota, Florida

Faculty, Lancaster Course in Ophthalmology
Colby College
Waterville, Maine

Glaucoma Faculty for Project Orbis
Yangon, Myanmar (Burma)

- 1992 Mini-course on Epidemiology and Biostatistics
New York Eye and Ear Infirmary
New York, New York
- 1992-1995 Member, ARVO Committee on Women and Minorities
Association for Research in Vision and Ophthalmology
- 1992-1995 Glaucoma 2001 Subcommittee on Risk Factors
American Academy of Ophthalmology
- 1993 Moderator, National Society to Prevent Blindness, Glaucoma
Symposium: *Glaucoma: The Common Pathway to Blindness*
American Academy of Ophthalmology
Chicago, Illinois
- 1993-1994 Public Health Committee
American Academy of Ophthalmology
- 1993-1996 Nominating Committee, American Glaucoma Society
- 1993-1996 Advisory Committee, Baltimore Eye Survey Follow-up Study
- 1993-1998 Glaucoma Detection Subcommittee
Prevent Blindness America
- 1993-2001 American Health Assistance Foundation,
National Glaucoma Research Scientific Committee
- 1993-2001 Scientific Advisory Board, Glaucoma Foundation
New York, New York
- 1993-2005 Glaucoma Advisory Committee
Prevent Blindness America
- 1994 Moderator, *Normal-tension Glaucoma/Ocular Blood Flow*
Association for Research in Vision and Ophthalmology
Sarasota, Florida
- Visiting Professor
King Khaled Eye Specialist Hospital
Riyadh, Saudi Arabia
- Co-Director, Epidemiology Course
Peking Union Medical College
Beijing, China
- 1994-1997 Nominating Committee
Prevent Blindness America
- 1994-2000 Basic and Clinical Science Course Committee
American Academy of Ophthalmology

- 1995 Visiting Faculty, Orbis International
Caribbean Regional Glaucoma Symposium
Kingston, Jamaica
- Moderator, *Glaucoma-New Ideas*
Association for Research in Vision and Ophthalmology
Faculty, Course 125, Glaucoma Basic and Clinical Science
Course: *Essentials of Glaucoma, What You Need to Know*
American Academy of Ophthalmology
Atlanta, Georgia
- 1995-1996 Honorary Advisory Board, Eyeville
- 1995-1998 Glaucoma Outcomes Committee
American Academy of Ophthalmology
- 1995-2002 Scientific Advisory Committee,
Glaucoma Research Foundation
San Francisco, California
- 1996 Moderator, *Epidemiology and Sociology in Glaucoma*
Association for Research in Vision and Ophthalmology
Fort Lauderdale, Florida
- 1996-1998 Member, Los Angeles County Medical Association (LACMA)
Task Force on Public/Private Relationships
- 1996-1998 Executive Committee, Los Angeles Society of Ophthalmology
- 1997 Moderator, *Glaucoma Clinical Research I*
Association for Research in Vision and Ophthalmology
Fort Lauderdale, Florida
- 1997-1998 Program Chairman, Los Angeles Society of Ophthalmology
- 1998 Moderator, *Glaucoma Clinical Pharmacology I*
Association for Research in Vision and Ophthalmology
Fort Lauderdale, Florida
- 1998 Faculty, Course 640, Glaucoma Basic and Clinical Science
Course: *Essentials of Glaucoma*
American Academy of Ophthalmology
New Orleans, Louisiana
- 1999-2008 Associate Examiner, American Board of Ophthalmology
- 1999-2011 Spencer Foreman Award for Outstanding Community Service
Selection Committee, Association of American Medical
Colleges (AAMC)

- 2000
Co-Director, Pre-Convention Scientific Symposia:
International Ophthalmology, National Medical Association
Washington, DC
- Faculty, Course 237, *Current Controversies in Glaucoma*
American Academy of Ophthalmology
Dallas, Texas
- Faculty, Course 465, *How To Critically Interpret Research
Results and to Translate These Results into Clinical Care*
American Academy of Ophthalmology
Dallas, Texas
- 2000-2003
Committee Member, Women's Health Initiative Council of Nebraska
- 2000-2005
Selection Committee, Herbert Nickens Minority Medical Student
Scholarships, AAMC
- 2001
Moderator, Oral Presentations Section
American Glaucoma Society
Las Vegas, Nevada
- Chairman, Epidemiology/Genetics Section
3rd International Glaucoma Symposium
Prague, Czech Republic
- Moderator, *Update in the Management of Glaucoma*
Co-Instructor, *Pitfalls and Pearls in the Use of
Drainage Devices*
XXIII Pan American Congress of Ophthalmology
Buenos Aires, Argentina
- Faculty, Course 116, *How to Critically Interpret Research
Results and to Translate These Results into Clinical Care*
American Academy of Ophthalmology
Dallas, Texas
- Moderator, *Professional Clinical Chairs Workshop on Minority
Faculty Development*
Case Western Reserve/University Hospitals Health System
Cleveland, Ohio
- Moderator, *Meeting Health Challenges of Emerging Populations
of Color*
Health and Human Services, Office of Minority Health and
Human Services
Omaha, Nebraska
- 2001-2002
Spring Meeting Planning Committee
Council of Deans, AAMC

- 2001-2002 National Advisory Committee, Howard University Research Centers in Minority Institutions (RCMI)
- 2001-2003 Committee Member, Nebraska EPSCOR (Experimental Program to Stimulate Competitive Research)
- 2002 Round Table Discussant, *Non-Penetrating Glaucoma Surgeries* 35th Panhellenic Ophthalmological Congress Chalkidiki, Greece
- Discussant, Meet the Experts-Fellows Program
OHTS: Implications for Clinical Practice
Orlando, Florida
- Nomination Committee, Association of Academic Health Centers
- Panel Discussant, *Faculty Recruitment*, National Medical Association 2002 Annual Convention and Scientific Assembly Honolulu, Hawaii
- 2002-2003 Xalatan Cultural Advisory Board, Pharmacia
- 2002-2003 Ocular Hypertension Treatment Study Advisory Board, Pharmacia
- 2002-2005 Glaucoma Risk Initiative Faculty, Pharmacia/Pfizer Ophthalmics
- 2002-2007 Glaucoma Advisory Board, Pfizer Ophthalmics
- 2003 Glaucoma Advisory Council, Allergan Pharmaceuticals
- Moderator, *Glaucoma Epidemiology and Genetics* 4th International Glaucoma Symposium Barcelona, Spain
- Moderator, AAO Glaucoma Subspecialty Day
Epidemiology and Global Perspective
Anaheim, California
- Discussion Chair, 1st Global AIGS Consensus Meeting on Structure and Function in the Management of Glaucoma: *Evidence Based Diagnosis* San Diego, California
- 2003-2006 Health-Related Institutions Formula Advisory Committee, Texas Higher Education Coordinating Board
- 2004 Roundtable Discussant, *Frontiers in Glaucoma* New Orleans, Louisiana

- Co-Chair, American Heart Association Heart Walk
- 2004-2005 Co-Chair, Association of International Glaucoma Society's
Committee on Global Research and Screening of Glaucoma
- 2004-2006 Health Outcomes Advisory Board, Allergan Pharmaceuticals
- 2004-2006 Task Force, Financial Barriers to Health Care in Texas
- 2004-2006 Advisory Board, Achievement Rewards for College Scientists
- 2005 Moderator, AAO Glaucoma Subspecialty Day
Which Ocular Hypertensive Patient Should Be Treated?
Chicago, Illinois
- 2005-2006 Co-Chair, Expert Panel
Rand Method for Assessing Glaucoma Therapy
- 2005-2006 Interim (Founding) Chair, Health Disparities Education,
Awareness, Research, and Training Consortium (HDEART)
President's Council
- 2005-2009 National Advisory Board, Undergraduate Medical Academy
- 2006 Moderator, AAO Glaucoma Subspecialty Day
Glaucoma: the Ophthalmologist's Dilemma
Las Vegas, Nevada
- Discussant, AAO Editor's Choice Symposium
*A Multicenter, Retrospective Pilot Study of Resource Use and
Costs Associated with Severity of Disease in Glaucoma*
Las Vegas, Nevada
- Deputy Director Search Committee, National Center on Minority
Health and Health Disparities, NIH
- Membership Committee, Association of Academic Health Centers
- 2006-2010 National Center on Minority Health and Health Disparities
Society of Fellows and Scholars, Charter Class
- 2006-2010 Advisory Board, World Glaucoma Association
- 2007 Moderator, International Glaucoma Society Session
Epidemiology and Geographical Glaucoma
Athens, Greece
- Chair, Didactic Session, World Glaucoma Congress
The Association of International Glaucoma Societies
Singapore

- Co-Chair, Course 30, *Design, Conduct, and Interpretation of Clinical Trails*
World Glaucoma Congress
The Association of International Glaucoma Societies
Singapore
- 2008
- Participant, 5th WGA Global Consensus Meeting for Screening Open Angle Glaucoma, Angle Closure and Angle Closure Glaucoma Consensus Development
Fort Lauderdale, Florida
- Panel Discussant, International Glaucoma Risk & Disease Management Symposium: *At Risk for Glaucoma*
University of Toronto
Ontario, Canada
- 2009
- Chair, *Epidemiology and Screening: Fundamental Issues Related to Screening for Disease*
World Glaucoma Congress
Boston, Massachusetts
- Faculty, Course 09, *Clinical Trials & Evidence-Based Glaucoma*
World Glaucoma Congress
Boston, Massachusetts
- Moderator, *Protecting the Academic Mission in the Face of Increasing Clinical Demands*
Association of Academic Health Centers
Inaugural Asia-Pacific Meeting
Singapore
- Panel Discussant, *The Experience of Member Universities in Handling Budget Cuts*
Association of Public and Land Grant Universities
Washington, DC
- 2010
- Co-Chair, *Intraocular Pressure in Clinical Practice: Minding the Gaps*
American Glaucoma Society
Naples, Florida
- Forum Participant, *Catalyzing University Research for a Stronger Economy*
Invitation from U.S. Secretary of Commerce, Gary Locke
Washington, DC
- Panel Discussant, *Legislative Attempts to Heal an Ailing Health System – Take 2 Aspirin and Call Us in 2010*
National Meeting of the American Bar Association
Denver, Colorado

Panel Discussant, *Discussion of Draft Statement Coming Out of the Five Regional Meetings on Public Research Universities*
Association of Public and Land Grant Universities
Washington, DC

Moderator, *Beyond Reform—The Role of Urban Universities in Closing the Health Workforce Gap*
The Coalition of Urban Serving Universities and The Association of Public and Land-Grant Universities' Commission on Urban Initiatives Joint Summer Meeting
Washington, D.C.

Organizer, *Developing Academic Health Center Metrics for Informed Decision-Making*
CEO Cluster Meeting, Association of Academic Health Centers
Washington, D.C.

Panel Discussant, *Institutions React to Stimulus and Reform*
Association of Academic Health Centers Annual Meeting
Dallas, Texas

Participant, Washington Ideas Forum
Sponsored by The Atlantic, Aspen Institute, and Newseum
Washington, D.C.

Organizer, Health Workforce Forum
Health Care Reform: Accelerating the Urban Health Workforce Imperative
Association of Public and Land-Grant Universities
Dallas, Texas

Participant, *The S³ Initiative: Share, Simplify, Streamline*
Council for American Medical Innovation
Washington, D.C.

2011

Discussion leader, *Social Determinants of Health*
AAHC International Forum: Collaborative Partnerships to Enhance Education, Science, and Population Health
Washington, D.C.

Section Moderator, *Academic Health Centers and the Social Determinants of Disease: Measuring our Success by our Population's Health*
Albuquerque, New Mexico

Moderator, Martin Luther King, Jr. Health Equity Summit
Washington, D.C.

2012-Current

Advisory Board, New Horizons Forum

San Francisco, California

2013- Panel Discussant, *Rapid Health Transitions: Findings and Implications of the Global Burden of Disease Study 2010*
Fogarty International Center, NIH
Bethesda, Maryland

Moderator, *Advancing New Horizons: Focusing on Collaboration and Public-Private Partnerships*
San Francisco, California

University/School Activities (selected 1986 to 1997 only)

1986-1990 Operating Room Committee
King/Drew Medical Center

1986-1994 Program Directors Committee
King/Drew Medical Center

1986-1994 Department of Surgery Executive Committee
King/Drew Medical Center

1986-1994 Clinical Appointments and Promotions Committee
Department of Ophthalmology
University of California, Los Angeles

1987-1988 Chairman, Search Committee for
Department of Internal Medicine Chairperson
Charles R. Drew University of Medicine and Science

1987-1994 Member, Grievance Committee
Charles R. Drew University of Medicine and Science

1987-1994 Advisory Board for International Health
Department of International Health
Charles R. Drew University of Medicine and Science

1987-1990 Associate Member, Jules Stein Eye Institute Committee

1989-1994 Director, Ophthalmic Epidemiology and Clinical Research Unit
Charles R. Drew University of Medicine and Science

1990 Jules Stein Eye Institute
Teaching Course: *Current Concepts for Glaucoma Management: Medical, Laser and Surgical, XXVI*
International Congress of Ophthalmology, Singapore

Moderator, Laser Section of 21st
JSEI Annual Postgraduate Seminar: *Glaucoma: Current Concepts in Diagnosis and Management*

Faculty, Combined Jules Stein/MLK
Postgraduate Laser Course and Workshop

1990-1998 Founding Chairman, Epidemiology and Clinical Vision
Research Study Group
Jules Stein Eye Institute, UCLA

1990-1998 Jules Stein Eye Institute Committee

1991 Course Co-Director, 1st Annual Doheny/JSEI Practical
Epidemiology and Biostatistics for Ophthalmologists
Faculty, JSEI Postgraduate Laser Course and Workshop

1991-1992 Chairman, Laser Committee, King/Drew Medical Center

1991-1993 International Health Research Committee
Department of International Health
Charles R. Drew University of Medicine and Science

1992 Course Co-Director, 2nd Annual JSEI/Doheny Practical
Epidemiology and Biostatistics for Ophthalmologists
Faculty, JSEI Postgraduate Laser Course and Workshop

1993 Course Director
Practical Epidemiology and Biostatistics for Ophthalmologists
Jules Stein Eye Institute, UCLA

1993-1994 Secretary-Treasurer, Professional Staff Association
King/Drew Medical Center

1993-1998 Founding Director, Center for Eye Epidemiology
Jules Stein Eye Institute, UCLA

1993-1995 Director, Jules Stein Eye Institute
Glaucoma Fellowship Selection Committee

1993-1995 Glaucoma Faculty Search Committee
Jules Stein Eye Institute, UCLA

1994 Course Director
Practical Epidemiology and Biostatistics for Ophthalmologists
Jules Stein Eye Institute, UCLA

1994-1998 Executive Committee, Charles Drew University of Med and
Science

1994-1998 Research Executive Committee
Charles R. Drew University of Medicine and Science

1994-1996 Advisory Committee
 Research Centers for Minority Institutions

1995 Course Co-Director, 25th Annual Jules Stein Eye Institute
 Postgraduate Seminar

 Faculty, Jules Stein/Drew
 Postgraduate Laser Course and Workshop

 Course Director
 Practical Epidemiology and Biostatistics for Ophthalmologists
 Jules Stein Eye Institute, UCLA

1995-1997 Glaucoma Division Chief Search Committee

1997 Course Director
 Practical Epidemiology and Biostatistics for Ophthalmologists
 Jules Stein Eye Institute, UCLA

 Clinical Scholars Program Policy Advisory Committee
 UCLA School of Medicine

Glaucoma Fellows Trained

Affiliation

1987-88: Jeffrey Schwartz	Eye Institute of West Florida Largo, Florida
1988-89: Clayton Berger	Broward Eye Clinic Fort Lauderdale, Florida
1989-90: Lawrence Goodwin	Private Practice Inglewood, California
Ilan Hartstein	La Palma Eye Center La Palma, California
1990-91: Jose Flavio Noriega	Clinical Assistant Professor Medico Cirujano Oftalmologo Benavides Miraflores, Chile
Jeffrey Rabowsky	Staff Member—Dept of Ophthalmology Permanente Medical Group Sacramento, California
Vincent Lee	Director of Eye Center Hong Kong Adventist Hospital Hong Kong
1991-92: Cordell Adams	Associate Attending Dept of Ophthalmology Baylor University Medical Center

	Dallas, Texas
1992-93: Ronit Kotas-Neumann	Staff Member-Eye Clinic Kfar-Saba, Israel
Jason Bacharach	Assistant Clinical Professor California Pacific Medical Center San Francisco, California
1993-94: Mae Tam	Associate Staff Member Dept of Ophthalmology Peach Arch Community Hospital Vancouver, Canada
Manolito Reyes	Consultant Ophthalmologist Reyes Eye Clinic/St. Victoria Hospital Metro Manila, Phillippines
1994-95: Irene Sasaki	Clinical Instructor Jules Stein Eye Institute/UCLA School of Medicine Los Angeles, California
Michael Kook	Visiting Professor, Dept of Ophthalmology University of Ulsan/College of Medicine Seoul, Korea
1995-96: Nicolas Hamush	Staff Member-McFarland Eye Clinic Ames, Iowa
Mary Bhavsar	Staff Member-Phillips Eye Institute Edina, Minnesota
1996-97: John Marsh	Staff Member-Hartland Eye Center Topeka, Kansas
Hung Huy Le	Private Practice Houston, Texas
Pedro Quevedo	Assistant Professor Clinica De Oftalmologia Cali, Columbia
1997-98: Fotis Topouzis	Associate Professor, Dept of Ophthalmology Aristotle University of Thessaloniki Thessaloniki, Greece
Simon Law	Associate Professor Jules Stein Eye Institute/UCLA School of Medicine

Grants (P.I. unless otherwise specified)

- 1984 National Research Service Award
Source: National Eye Institute, NIH
Amount: \$18,000
- 1985 Glaucoma Prevalence Study
Source: Agency for International Development
Amount: \$100,000 (Direct cost)
Total Project Cost: \$400,000 (Estimated)
- 1986 Mitomycin for Pterygium Therapy
Source: Biomedical Research Support Grant/Charles R. Drew University of Medicine and Science
Amount: \$1,505
- 1986 An Evaluation of the Acceptance and Ease of Use of a Reminder Cap in Subjects Using a Tropical Medication Two Times a Day
Source: Allergan Pharmaceuticals
Amount: \$2,250
- 1987 A Clinical Evaluation of the Safety and Efficacy of Ofloxacin vs. Tobramycin External Ocular Infections
Source: Allergan Pharmaceuticals
Amount: \$4,500
- 1988 Levobunolol vs. Dipivefrin as the Initial Treatment of Black Glaucoma Patients
Source: Allergan Pharmaceuticals
Amount: \$20,000
- 1988 Mitomycin and Filters
Source: Biomedical Research Support Grant/Charles R. Drew University of Medicine and Science
Amount: \$2,000
- 1989 A Phase II Multiple-Dose Study of Abbott-64662 Ophthalmic Solution Administered Three Times-A-Day to Patients with Elevated Intraocular
Source: Abbott Laboratories
Amount: \$29,550
- 1991 Eye Injury in Los Angeles
Source: Southern California Injury Prevention Research Center
Amount: \$10,000
- 1991 Blindness and Visual Impairment in Cameroon, West Africa
Source: Agency for International Development
Amount: \$100,000 (Direct cost)
Total Project Cost: \$700,000 (Estimated)

- 1992 Evaluation of Metipranolol/Pilocarpine Ocular Drops in Treating Open Angle Glaucoma and Ocular Hypertension
Source: Bausch and Lomb Pharmaceuticals
Amount: \$55,625
- 1993 Ocular Hypertension Treatment Study (OHTS) Clinical Center
Source: National Eye Institute, NIH
Amount: \$738,286 (5 years)
- 1994 Population Based Study of Functional Visual Impairment in South-East Los Angeles (Co-investigator)
Source: National Center for Research Resources, NIH
Amount: \$240,000 (4 Years)
- 1994 Depression and Glaucoma
Source: Research to Prevent Blindness
Amount: \$20,000
- 1994 Health Related Quality of Life in Glaucoma Patients (Co-principal Investigator)
Source: Glaucoma Research Foundation
Amount: \$100,000
- 1995 A Randomized, Double-Masked, Multicenter, Parallel Study Comparing the Effects of Carteolol and Timolol Ophthalmic Solution
Source: Otsuka America Pharmaceutical
Amount: \$31,824
- 1995 Ocular Hypertension Treatment Study
Ancillary Study: Heidelberg Retinal Tomography Clinical Center
Source: National Eye Institute, NIH
Amount: \$74,000 (3 years)
- 1996 Cataract Management Trial: Visual Function and Costs (Co-Investigator)
Source: Claude D. Pepper Geriatric Research and Training Center, NIH
Amount: \$656,505 (5 years)
- 1997 Research Centers for Minority Institutions, Core Infrastructure Development Grant
Source: National Center for Research Resources, NIH
Amount: \$4,257,080 (5 years)
- 1997 Ocular Hypertension Treatment Study
Ancillary Study: Heidelberg Retinal Tomography Clinical Center (Co-PI)
Source: National Eye Institute, NIH
Amount: \$70,000 (5 years)

1997	Clinical Trials Unit Source: National Center for Research Resources, NIH Amount: \$7,931,717 (6 years)
1997	Center for Eye Epidemiology (JSEI, UCLA) Source: Ahmanson Foundation Amount: \$1,000,000
1999	Pipeline to Success at Creighton University Source: Health Resources and Services Administration (HRSA), DHHS Amount: \$1,285,105 (3 years)
1999	Health Professions Partnership Initiative (Creighton University) Source: Robert Wood Johnson Foundation Amount: \$347,243 (5 years)
2001	Thessaloniki Eye Study Source: International Glaucoma Association Amount: \$50,000
2002	African Descent and Glaucoma Evaluation Study (Consultant) Source: National Eye Institute, NIH Amount: \$13,169,312 (7 years)
2002	Thessaloniki Eye Study Source: Health Future Foundation Amount: \$47,870
2002	CO6 RR 17417-01 Source: National Centers for Research Resources, NIH Amount: \$2,000,000
2003	Center of Excellence, Section 736 (Creighton University) Source: Health Resources and Services Administration (HRSA), DHHS Amount: \$1,692,153 (3 years)
2004	Thessaloniki Eye Study Source: Texas Tech University Health Sciences Center Amount: \$25,000

Invited Presentations

1. *Epidemiology of Glaucoma*. National Medical Association Conference. Dallas, Texas. July 1980.
2. *Effect of Race on Open-Angle Glaucoma*. Joint Annual Meeting of the Massachusetts Eye and Ear Infirmary Alumni Association and New England Ophthalmological Society. Boston, Massachusetts. April 1984.

3. *Glaucoma in Blacks*. National Medical Association Conference. July 1984.
4. *Glaucoma Epidemiology*. Glaucoma Update Course Massachusetts Eye and Ear Infirmary, Harvard Medical School, Department of Continuing Education. Boston, Massachusetts. March 1985.
5. *Diagnostic Dilemmas In Angle Closure Glaucoma*. National Medical Association Conference, New Orleans. Louisiana. August 1987.
6. *Diagnosis and Treatment of Patients With Narrow Angles*. Cedars-Sinai Ophthalmology Staff Continuing Education. Los Angeles, California. October 1987.
7. *National Survey of the Prevalence of Glaucoma in St. Lucia, West Indies*. 12th Annual UCLA Department of Ophthalmology Association Clinical Conference. Los Angeles, California. December 1987.
8. *Blood Induced Glaucomas*. Grand Rounds Jules Stein Eye Institute. Los Angeles, California. March 1988.
9. *Special Considerations of Glaucoma in Blacks*. National Medical Association. Los Angeles, California. August 1988.
10. *Glaucoma and Trauma*. Fifth Annual Bangkok Ophthalmology Meeting. Bangkok, Thailand. January 1989.
11. *Post-Surgical Glaucomas*. Fifth Annual Bangkok Ophthalmology Meeting. Bangkok, Thailand. January 1989.
12. *Racial Differences in Therapeutic Responsiveness to Glaucoma Agents*. The Second Caribbean Glaucoma Symposium. St. Thomas, Virgin Islands. March 1989.
13. *Narrow Angle Glaucoma: Pearls and Pitfalls*. The Second Caribbean Glaucoma Symposium. St. Thomas, Virgin Islands. March 1989.
14. *Glaucoma After Cataract Surgery*. National University Hospital. Singapore. January 1990.
15. *Epidemiology and Treatment of Narrow Angles*. National University Hospital. Singapore. January 1990.
16. *Changing Views on Angle-Closure Glaucoma*. Western Regional Update Course American Academy of Ophthalmology. Irvine, California. February 1990.
17. *Practical Classification of the Glaucomas (Gonioscopy)*. Western Regional Update Course American Academy of Ophthalmology. Irvine, California. February 1990.
18. *Why Do People Go Blind From Glaucoma?* New England Ophthalmology Society W. Morton Grant Festschrift. Boston, Massachusetts. March 1990.
19. *Epidemiology of Glaucoma*. XXVI International Congress of Ophthalmology. Singapore. March 1990.

20. *Epidemiology of Glaucoma*. 21st JSEI Annual Postgraduate Seminar. Los Angeles, California. April 1990.
21. *Performing Gonioscopy and Diagramming Angles*. Cedars-Sinai Ophthalmology Staff Continuing Education Program. Los Angeles, California. July 1990.
22. *Angle Closure Glaucoma*. Memorial Hospital Medical Center of Long Beach Continuing Education Program. Long Beach, California. November 1990.
23. *What Do We Know About Glaucoma Risk Factors?* Research Study Club of Los Angeles. Los Angeles, California. February 1991.
24. *What Does Epidemiology Have To Do With Ophthalmology?* 1st Annual Doheny/JSEI Practical Epidemiology and Biostatistics for Ophthalmologists. Los Angeles, California. February 1991.
25. *Diabetes 2000*. NEI, National Eye Health Education Program. Hilton Head, South Carolina. February 1991.
26. *Prognostic Factors in Glaucoma Filtering Surgery*. 22nd JSEI Annual Postgraduate Seminar, Los Angeles, California. March 1991.
27. *Glaucoma Filtration Surgery: Pearls and Perils*. National Medical Association Conference, Indianapolis, Indiana. July 1991.
28. *Risk Assessment in Glaucoma*. International Glaucoma Symposium, Jerusalem, Israel. August 1991.
29. *Is IOP the Cause of Glaucoma?* Beilinson Medical Center. Tel Aviv, Israel. August 1991.
30. *Risks in Glaucoma Surgery*. Update Course in Ophthalmology (Curso de Actualizacion Oftalmologica). Los Angeles, California. October 1991.
31. *Glaucoma in the Diabetic Patient: Pathophysiology*. Diabetes 2000 Symposium American Academy of Ophthalmology Meeting. Anaheim, California. October 1991.
32. *Epidemiology and Pathophysiology of Narrow Angles and Angle Closure Glaucoma*. National Hospital. Yangon, Myanmar. November 1991.
33. *A Critical Look at Glaucoma Risk Factors*. Grand Rounds JSEI. Los Angeles, California. January 1992.
34. *POAG: Epidemiology and Risk Factors*. Visiting Professor, University of California at San Francisco. San Francisco, California. May 1992.
35. *Prevalence and Incidence of Glaucoma: Who Has It and Who Gets It?* Current Ophthalmic Practice Symposium, Jules Stein Eye Institute. Los Angeles, California. June 1992.
36. *Prevalence and Incidence of Glaucoma: Who Has It and Who Gets It?* 1992 Summer Institute American Academy of Ophthalmology. San Francisco, California. July 1992.
37. *Eliminating Preventable Blindness From Diabetes by the Year 2000*. Diabetes Complications Symposium, National Medical Association Conference. San Francisco, California. August 1992.

38. *Neovascular Glaucoma: Pathophysiology and Management*. National Medical Association Conference. San Francisco, California. August 1992
39. *Glaucoma After Trauma*. California Association of Ophthalmology, 11th Annual Educational Conference. Dana Point, California. September 1992.
40. *Blebs: Prognostic Factors for Survival and Influencing Its Function*. Xth International Congress of Eye Research. Stresa, Italy. September 1992.
41. *Epidemiology of Open Angle Glaucoma*. Conference at Morehouse School of Medicine, Glaucoma in the Afro-American: The Forgotten Majority. Atlanta, Georgia. January 1993.
42. *Neovascular Glaucomas*. Conference at Morehouse School of Medicine, Glaucoma in the Afro-American: The Forgotten Majority. Atlanta, Georgia. January 1993.
43. *New Concepts in Neovascularization*. Grand Rounds, JSEI. Los Angeles, California. February 1993.
44. *Mitomycin C in Glaucoma Filtration Surgery: Who, How, Why, and Why Not*. Research Study Club of Los Angeles, 62nd Annual Mid-Winter Clinical Conference. Los Angeles, California. February 1993.
45. *Racial Considerations in the Diagnosis and Management of Glaucoma*. The Fourth Caribbean Glaucoma Symposium. St. Thomas, Virgin Islands. March 1993.
46. *Short Update on Mitomycin*. Medical Staff Meeting, JSE. Los Angeles, California. March 1993.
47. *Risk Factors for Glaucoma: Fact or Fiction?* Visiting Professor, University of California at San Diego. San Diego, California. April 1993.
48. *Screening for Diabetic Retinopathy: The Primary Care Physician's Role*. "Academics at Midway" CME Program, Midway Hospital Medical Center. Los Angeles, California. April 1993.
49. *Practical Tips on Using Mitomycin-C*. Current Ophthalmic Practice Seminar, Mercy Health Care Hospital. Bakersfield, California. May 1993.
50. *Antimetabolites in Glaucoma Filtration Surgery*. National Medical Association Conference. San Antonio, Texas. August 1993.
51. *Update on Diabetes 2000*. Pre-Convention Diabetes Symposium, National Medical Association. San Antonio, Texas. August 1993.
52. *Optimizing Surgical and Laser Therapy in Glaucoma*. Glaucoma in the Developing World Symposium. Montego Bay, Jamaica. September 1993.
53. *Prevalence and Causes of Blindness in the Extreme North Province of Cameroon*. Cameroon. West Africa. November 1993.
54. *Update on the Use of Antimetabolites in Filtration Surgery*. Glaucoma Update 1993 Conference, University of California. Irvine, California. December 1993.

55. *IOP: Evolving Concepts and Its Influence on the Management of Glaucoma*. Grand Rounds, JSEI. Los Angeles, California. February 1994.
56. *Sturge Weber Syndrome*. 24th JSEI Annual Postgraduate Seminar. Los Angeles, California. April 1994.
57. *What All Primary Care Eye Providers Must Know About Glaucoma?* Ocular Symposium: Pearls in Ocular Diagnosis. Universal City, California. May 1994.
58. *Glaucoma Implant Surgery*. Grand Rounds. Riyadh, Saudi Arabia. July 1994.
59. *Repairing Leaking Blebs*. Grand Rounds. Riyadh, Saudi Arabia. July 1994.
60. *Recent Advances in Risk Factor Research*. Research Conference. Riyadh, Saudi Arabia. July 1994.
61. *Glaucoma Filtration Surgery: Pearls and Pitfalls*. University Eye Hospital. Columbo, Sri Lanka. August 1994.
62. *Another Perspective on Intraocular Pressure*. New England Ophthalmological Society/Massachusetts Eye and Ear Alumni Scientific Meeting. Boston, Massachusetts. October 1994.
63. *Risk Factors for Glaucoma*. Pre-Academy Glaucoma Symposium. San Francisco, California. October 1994.
64. *Demographics of Glaucoma: Focusing on the High Risk Groups*. American Academy of Ophthalmology/National Society to Prevent Blindness Glaucoma Symposium. San Francisco, California. October 1994.
65. *Discussion of Paper: Racial Differences in Optic Nerve Head Topography*. American Academy of Ophthalmology. San Francisco, California. October 1994.
66. *Clinical Trials and Longitudinal Studies: How They Are Influencing Glaucoma Management*. 25th JSEI Annual Postgraduate Seminar. Los Angeles, California. April 1995.
67. *Nuts and Bolts of Glaucoma Evaluation*. Ocular Symposium. Universal City, California. April 1995.
68. *Antimetabolites in Glaucoma Filtration Surgery*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.
69. *Review of Glaucoma Implants: Principles and Practices*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.
70. *The Ahmed Glaucoma Valve Implant: The UCLA Experience*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.
71. *Update on Assessing Optic Nerve Head Topography*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.

72. *Current Trends in Glaucoma Management*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.
73. *Epidemiological Features of Glaucoma*. Third Annual International Ophthalmology Conference. Cali, Colombia. May 1995.
74. *Review of Glaucoma Implants: Principles and Practices*. Current Ophthalmic Practice Seminar, Cottage Hospital. Santa Barbara, California. June 1995.
75. *Confocal Laser Imaging of the Optic Nerve Head*. Current Ophthalmic Practice Seminar, Cottage Hospital. Santa Barbara, California. June 1995.
76. *Low Tension Glaucoma: Another Perspective*. International Symposium on Modern Challenges of Ophthalmology and Visual Sciences. Hong Kong. July 1995.
77. *Practical Tips on Performing Glaucoma Implant Surgery*. Shanghai Second Medical School. Shanghai, China. July 1995.
78. *The Ahmed Glaucoma Valve Implant: Theory, Indications, Technique, and Clinical Experience*. University of Indonesia. Jakarta, Indonesia. July 1995.
79. *Comparison of Currently Available Glaucoma Drainage Implants*. National Medical Association Conference. Atlanta, Georgia. August 1995.
80. *Glaucoma Implants*. Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Columbo. Columbo, Sri Lanka. August 1995.
81. *Low Tension Glaucoma*. Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Columbo. Columbo, Sri Lanka. August 1995.
82. *Interpreting Automated Perimetry*. Invited College Lecture, College of Ophthalmologists of Sri Lanka, University of Columbo. Columbo, Sri Lanka. August 1995.
83. *Nuts and Bolts of Glaucoma Evaluation: Gonioscopy, Optic Nerve Assessment, and Visual Fields*. National Optometric Association, Southern California Chapter. Monterey Park, California. September 1995.
84. *Update on the Ocular Hypertension Treatment Study*. National Optometric Association, Southern California Chapter. Monterey Park, California. September 1995.
85. *Discussion of Paper: Routine Eye Care is Essential for Preventing Blinding Eye Disease*. American Academy of Ophthalmology. Atlanta, Georgia. October 1995.
86. *Low Tension Glaucoma*. Research Study Club, Los Angeles, California. February 1996.
87. *Clinical Trials: How They Have Influenced Glaucoma Management*. Research Study Club. Los Angeles, California. February 1996.
88. *Glaucoma in the Caribbean*. Ophthalmological Society of West Indies. Barbados, West Indies. July 1996

89. *Glaucoma Screening and Control Strategies*. Ophthalmological Society of West Indies, Barbados. West Indies. July 1996.
90. *A Perspective on Intraocular Pressure and Glaucoma*. National Medical Association Conference. Chicago, Illinois. July 1996.
91. *Clinical Trials: Value and Impact*. American Academy of Ophthalmology/Prevent Blindness Glaucoma Symposium. Chicago, Illinois. October 1996.
92. *Newer Techniques in Glaucoma Management: Glaucoma Drainage Devices*. All India Ophthalmology Society Conference. New Delhi, India. February 1997.
93. *Glaucoma Clinical Trials: Their impact on How We Currently Manage Glaucoma*. All India Ophthalmology Society Conference. New Delhi, India. February 1997.
94. *Practical Tips on Glaucoma Management*. All India Institute of Medical Sciences. New Delhi, India. February 1997.
95. *Glaucoma Clinical Trials: How They Influence How We Practice*. Society of Air Force Clinical Surgeons, 44th Annual Symposium. Sacramento, California. April 1997.
96. *Argon Laser Trabeculoplasty*. Lasers in Ophthalmology Course, Jules Stein Eye Institute UCLA. Los Angeles, California. September 1997.
97. *Laser Peripheral Iridotomy*. Lasers in Ophthalmology Course, Jules Stein Eye Institute UCLA, Los Angeles. California. September 1997.
98. *What Causes Glaucoma?* Ahmedabad Academy of Ophthalmology. Ahmedabad, India. September 1997.
99. *Glaucoma Clinical Trials Update*. Ahmedabad Academy of Ophthalmology. Ahmedabad, India. September 1997.
100. *The Meat and Potatoes of Epidemiology*. American Glaucoma Society, Mini-Symposium. Scottsdale, Arizona. December 1997.
101. *Depression and Quality of Life in Glaucoma Patients*. National Glaucoma Research Symposium, American Health Assistance Foundation, 25th Anniversary Program. San Diego, California. January 1998.
102. *Normal Tension Glaucoma: IOP as a Causative Factor*. Glaucoma Symposium, 28th International Congress of Ophthalmology. Amsterdam, The Netherlands. June 1998.
103. *Health Status and Quality of Life Measures*. Visiting Professor, University of Maryland. Baltimore, Maryland. July 1998.
104. *Update of Quality of Life in Glaucoma Patients*. National Medical Association Conference. New Orleans, Louisiana. August 1998.
105. *Early Diagnosis is Unimportant*. Subspecialty Day, American Academy of Ophthalmology. New Orleans, Louisiana. November 1998.

106. *Clinical Trial of Trabeculectomy versus Ahmed Implant*. American Glaucoma Society. Amelia Island, Florida. February 1999.
107. *Health-Related Quality of Life in Cataract and Glaucoma*. Omaha Ophthalmological Society. Omaha, Nebraska. March 1999.
108. *Epidemiology of Glaucoma*. Harvard School of Public Health. Boston, Massachusetts. March 1999.
109. *Consideration of Glaucoma Surgery from a Worldwide Perspective*. Jules Stein Eye Institute Postgraduate Seminar. Los Angeles, California. April 1999.
110. *Natural History of Glaucoma*. Jules Stein Eye Institute Postgraduate Seminar. Los Angeles, California. April 1999.
111. *Diversity in Health Science Education*. University of Nebraska Medical Center. Omaha, Nebraska. May 1999.
112. *Minority Physicians: What Are Our Obligations?* Harvard Medical Alumni Association. Boston, Massachusetts. June 1999.
113. *The Natural History of Glaucoma: Implications of the St. Lucia Follow-up Study*. The 2nd Congress of Ophthalmology, University of San Paulo. San Paulo, Brazil. November 1999.
114. *Quality of Life In Glaucoma and Cataract*. The 2nd Congress of Ophthalmology, University of San Paulo. San Paulo, Brazil. November 1999.
115. *Trabeculectomy versus Ahmed Implant Clinical Trial Results*. The 2nd Congress of Ophthalmology, University of San Paulo. San Paulo, Brazil. November 1999.
116. *Perspective on Glaucoma Screening*. The 2nd Congress of Ophthalmology, University of San Paulo. San Paulo, Brazil. November 1999.
117. *Clinical Trial Update*. The 2nd Congress of Ophthalmology, University of San Paulo. San Paulo, Brazil. November 1999.
118. *Who Should Be Screened For Glaucoma and How Should It Be* The Links, Incorporated. Philadelphia, Pennsylvania. December 1999.
119. *Introduction to Mission Based Management*. Association of Medical School Pediatric Department Chairs. Annual Meeting. San Diego, California. March 2000.
120. *Normal Tension Glaucoma*. Italian Association for the Study of Glaucoma. Rapallo, Italy. March 2000.
121. *Incidence of Glaucoma and Progression of Glaucoma*. University of Colorado 4th Annual Ophthalmology Symposium. Denver, Colorado. March 2000.
122. *Clinical Trial of Trabeculectomy vs. Ahmed Implant: Long Term Results*. University of Colorado 4th Annual Ophthalmology Symposium. Denver, Colorado. March 2000.

123. *Health Related Quality of Life: Implications for Glaucoma.* University of Colorado 4th Annual Ophthalmology Symposium. Denver, Colorado. March 2000.
124. *Decision Making – Indications for Combined Surgery.* East Coast Glaucoma Symposium. New York, New York. May 2000.
125. *How Should I Screen for Glaucoma?* East Coast Glaucoma Symposium. New York, New York. May 2000.
126. *From St. Lucia to The Cameroons: Infrastructure Needs for Research and Clinical Care.* National Medical Association. Washington DC. August 2000.
127. *Screening for Glaucoma in High Risk Populations.* Congressional Glaucoma Caucus Foundation. Washington DC. August 2000.
128. *Is IOP Merely a Risk Factor for Glaucomatous Injury or an Intrinsic Part of the Disease?* Glaucoma 2000 Subspecialty Day, American Academy of Ophthalmology. Dallas, Texas. October 2000.
129. *St. Lucia Follow-up Study: The Natural History of Glaucoma.* American Glaucoma Society. Newport Beach, California. February 2001.
130. *Achieving Better Health for All Americans.* Nebraska Alzheimer Association and the Center for Aging, Alzheimer and Neurodegenerative Diseases, Omaha, Nebraska. August 2001.
131. *Racial Differences in Prevalence of Eye Diseases: Now What?* University of Colorado 5th Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
132. *How Fast Do Visual Fields Progress in Treated and Untreated Eye?* University of Colorado 5th Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
133. *Strategies for Glaucoma Screening: One Size Does Not Fit All.* University of Colorado 5th Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
134. *What Have We Learned from the Normal Tension Glaucoma Treatment Trial?* University of Colorado 5th Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
135. *When Should Glaucoma Drainage Implants Be Used?* University of Colorado 5th Annual Ophthalmology Symposium. Denver, Colorado. September 2001.
136. *Making Opportunities Available for Students of Diverse Backgrounds.* Keynote Speaker, Northeastern Ohio Universities College of Medicine. Akron, Ohio. October 2001.
137. *Should Treatment of Glaucoma In Blacks Differ?* Glaucoma 2001 Subspecialty Day, American Academy of Ophthalmology. New Orleans, Louisiana. November 2001.
138. *Societal Burden of Glaucoma.* American Academy of Ophthalmology/Prevent Blindness America Glaucoma Symposium. New Orleans, Louisiana. November 2001.

139. *Worldwide Implications of the Challenges of Health Care Delivery in Glaucoma*. American Academy of Ophthalmology/Prevent Blindness, America Glaucoma Symposium. New Orleans, Louisiana. November 2001.
140. *Glaucoma: What You Don't Know Could Blind You*. Keynote Speaker: Glaucoma Awareness Month Kick-off Event, St. Joseph Hospital. Omaha, Nebraska. January 2002.
141. *Visual Field Progression in Glaucoma – How Often and How Fast!* 35th Panhellenic Ophthalmological Congress. Halkidiki, Greece. June 2002.
142. *Glaucoma in the Caribbean: Implications for Glaucoma in African Americans*. National Medical Association 2002 Annual Convention and Scientific Assembly. Honolulu, Hawaii. August 2002.
143. *Race and Glaucoma: Beyond Prevalence*. National Medical Association 2002 Annual Convention and Scientific Assembly. Honolulu, Hawaii. August 2002.
144. *Quality of Life and Therapy: Is it Worth Treating?* Commemoration of the 20th Anniversary of the Baltimore Eye Survey. Baltimore, Maryland. September 2002.
145. *OHTS: Implications for Clinical Practice?* Glaucoma 2002 Subspecialty Day, American Academy of Ophthalmology. Orlando, Florida. October 2002.
146. *Recent Advances in Glaucoma: Results of the Ocular Hypertension Treatment Study*. Orlando, Florida. October 2002.
147. *OHTS: Do I Need to Treat Everybody?* New York Society for Clinical Ophthalmology, Winter Meeting. New York, New York. December 2002.
148. *Normal Tension Glaucoma: History and Epidemiology*. 4th Japan Glaucoma Council. Tokyo, Japan. December 2002.
149. *Evidence Based Medicine: Role of the Reviewer*, Glaucoma Specialists Consultants Meeting. New York, New York. December 2002.
150. *Lessons Learned from Glaucoma Epidemiological Studies and Application to Clinical Practice*. Glaucoma Symposium. Thessaloniki, Greece. January 2003.
151. *OHTS: From the Results to Clinical Practice*. Glaucoma Symposium. Thessaloniki, Greece. January 2003.
152. *OHTS Risk Factors*. OH: Defining Risk & Clinical Options. Las Vegas, Nevada. January 2003.
153. *Epidemiology and Risk Factors for Glaucoma and Glaucoma Blindness*. Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute. Cleveland, Ohio. March 2003.
154. *A Perspective on Race and Glaucoma*. Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute. Cleveland, Ohio. March 2003.
155. *Should Glaucoma Drainage Implants Be Used for Initial Surgery of Uncomplicated Glaucoma?* Glaucoma Summit 2003: Vision for the Future, Cole Eye Institute. Cleveland, Ohio. March 2003.

156. *Evidence Based Medicine: A New Approach to Glaucoma*. American Glaucoma Society 2003 Annual Meeting. San Francisco, California. March 2003.
157. *Multi Center Clinical Studies: Clinical Implications of OHTS*. 4th International Glaucoma Symposium. Barcelona, Spain. April 2003.
158. *Randomized Controlled Trials of Therapy in Glaucoma. The Glaucoma Laser Trial*. Glaucoma Society of the International Congress of Ophthalmology. Chantilly, France. May 2003.
159. *Randomized Controlled Trials of Therapy in Glaucoma. Global Perspectives on RCTS – A North American View*. Glaucoma Society of the International Congress of Ophthalmology. Chantilly, France. May 2003.
160. *Pipeline to Success at Creighton University: Pathways to Increased Student Retention*. National Association of Medical Minority Educators, Inc. Kansas City, Missouri. September 2003.
161. *Academic Health Science Center's Role in Economic Development of the Community*. Downtown Chapter of the American Business Club. Lubbock, Texas. November 2003.
162. *An Argument for Switching Rather than Adding Glaucoma Medication*. Bascom Palmer Eye Institute Glaucoma Mid-Winter Symposium. Coral Gables, Florida. January 2004.
163. *Every mmHg Reduction is Important in the Treatment of Glaucoma*. Bascom Palmer Eye Institute Glaucoma Mid-Winter Symposium. Coral Gables, Florida. January 2004.
164. *A Call to Action for Better Health for our Community*. Keynote Speaker, Mt. Vernon United Methodist Church. Lubbock, Texas. February 2004.
165. *Health Disparities from Cancer in West Texas*. Texas Cancer Council. Austin, Texas. February 2004.
166. *Leadership in Medicine*. Alpha Omega Alpha. Lubbock, Texas. April 2004.
167. *Lessons Learned from Glaucoma Epidemiological Studies and Application to Clinical Practice*. Beijing International Glaucoma Conference. Beijing, China. April 2004.
168. *Lighting the Path to Preeminence*. Texas Tech University Health Sciences Center Symposium. Lubbock, Texas. April 2004.
169. *Strategies for Glaucoma Screening*. Update on Therapeutic Treatments for Glaucoma. Chicago, Illinois. May 2004.
170. *Does 1 mmHG of Pressure Lowering Matter?* Update on Therapeutic Treatments for Glaucoma. Chicago, Illinois. May 2004.
171. *Switching vs. Adding Medication*. Update on Therapeutic Treatments for Glaucoma. Chicago, Illinois. May 2004.
172. *Collaborative Normal-Tension Glaucoma Trial*. Update on Therapeutic Treatments for Glaucoma. Chicago, Illinois. May 2004.

173. *Health Care: Ensuring Better Access, Benefits, Choices, and Healthy Lifestyles*. National African American Leadership Summit, Invitation from Senator Kay Bailey Hutchison. Washington DC. May 2004.
174. *Projecting Progression Rates in Glaucoma*. 7th Congress of the European Glaucoma Society. Florence, Italy. May 2004.
175. *Toward a Bi-national Cooperation for Medical Education*. Border Health Forum. Juarez, Mexico. June 2004.
176. *Disparities in Health in America: Working Toward Social Justice*. 2004 Summer Health Disparities Workshop, The Center for Research on Minority Health at University of Texas M.D. Anderson Cancer Center. Houston, Texas. June 2004.
177. *The Glaucoma Continuum*. Boston, Massachusetts. July 2004.
178. *Cameroon Eye Study*. Third Annual Research Day, Texas Tech University School of Pharmacy. Amarillo, Texas. July 2004.
179. *Applying Evidence-based Medicine (EBM) in Everyday Ophthalmic Practice*. Boston, Massachusetts. August 2004.
180. *Global Risk Assessment of Multiple Risk Factors*. Boston, Massachusetts. August 2004.
181. *Translating Risk into Clinical Practice: What is the Threshold for Therapy?* Glaucoma 2004 Subspecialty Day, American Academy of Ophthalmology. New Orleans, Louisiana. October 2004.
182. *Global Glaucoma Perspective-Epidemiology*. Glaucoma Specialists Forum. Las Colinas, Texas. November 2004.
183. *All Is Not Well: Improving the Health of the Community*. Community Baptist Church. Lubbock, Texas. February 2005.
184. *Racial and Ethnic Disparities in Diseases and Outcomes*. Update for the Comprehensive Ophthalmologist Meeting. Lubbock, Texas. June 2005.
185. *Value-Based Medicine*. Association of International Glaucoma Societies World Glaucoma Congress. Vienna, Austria. July 2005.
186. *Ethnicity-Race. Considering Population-based Studies in Different Populations*. From Research to Clinical Practice: Thessaloniki Eye Study- First Results, Aristotle University of Thessaloniki Department of Ophthalmology. Thessaloniki, Greece. September 2005.
187. *Clinical Trials: Special Challenges and Opportunities Related to Minority Populations*. 2005 Annual Meeting, Association of Academic Health Centers. Ponte Vedra Beach, Florida. September 2005.
188. *Treatment of Risk in the Glaucoma Continuum: The Glaucoma Continuu*. Miami, Florida. November 2005.
189. *Glaucoma and You*. Coalition of African American Churches. Dallas, Texas. February 2006.

190. *A Vision in Glaucoma*. Black Faculty/Staff Association Health Fair. Lubbock, Texas. February 2006.
191. *Glaucoma: Landmark Clinical Trials and Their Impact on Practice*. 13th International Glaucoma Congress. Athens, Greece. March 2006.
192. *Risk Calculation and Glaucoma Management in the "Glaucoma Continuum."* 39th Panhellenic Ophthalmological Congress. Thessaloniki, Greece. June 2006.
193. *Empowering Communities Through Committed Service*. Guest speaker for the Lubbock Alumnae Chapter of Delta Sigma Theta's "Man and Woman of the Year Community Service Award" program. Lubbock, Texas. June 2006.
194. *Identification and Screening—Background*. Glaucoma Society, International Congress of Ophthalmology. Vancouver, Canada. June 2006.
195. *Pharmacologic Treatment Worldwide Issues—Pharmacogenetics and Ethnicity*. Glaucoma Society, International Congress of Ophthalmology. Vancouver, Canada. June 2006.
196. *Searching for Diversity: Conducting Successful Searches*. Association of American Medical Colleges 2006 Annual Meeting. Seattle, Washington. October 2006.
197. *Medical Education and the Public Trust*. Plenary Session. Western Group on Student Affairs Spring 2007 Meeting. Asilomar, California. April 2007.
198. *Celebrating Scholars and Scholarships*. Boule Scholarship Dinner Lecture. Denver, Colorado. May 2007.
199. *University and Entrepreneurship*. Bard Center for Entrepreneurship awards program. Denver, Colorado. June 2007.
200. *Design, Conduct and Interpretation of Clinical Trials: Pearls and Pitfalls*. World Glaucoma Congress. The Association of International Glaucoma Societies. Singapore. July 2007.
201. *Closing the Achievement Gap: Educating for Success in a Competitive Marketplace*. National African American Leadership Summit. Invitation from Senator Kay Bailey Hutchison. Washington, DC. July 2007.
202. *Reactions and Comment: The Nation's Health Workforce*. Association of Academic Health Centers 2007 Annual Meeting. Philadelphia, Pennsylvania. October 2007.
203. *How Common is Progression?* American Academy of Ophthalmology/Prevent Blindness America Glaucoma Symposium. New Orleans, Louisiana. November 2007.
204. *Reflections on Glaucoma: 1986-2006*. Philippine Glaucoma Congress. The Philippine Glaucoma Society 10th Anniversary. Manila, Philippines. February 2008.
205. *Risk Factor: The Birth, The Evolution and The Practice*. Philippine Glaucoma Congress. The Philippine Glaucoma Society 10th Anniversary. Manila, Philippines. February 2008.

206. *Current Approach to the Medical Treatment of Glaucoma*. Philippine Glaucoma Congress. The Philippine Glaucoma Society 10th Anniversary. Manila, Philippines. February 2008.
207. *Glaucoma Drainage Devices*. Philippine Glaucoma Congress. The Philippine Glaucoma Society 10th Anniversary. Manila, Philippines. February 2008.
208. *Risk Factor: The Birth, The Evolution, and The Practice*. Harvard Visiting Lecture. Boston, Massachusetts. March 2008.
209. *Blindness and Low Vision Survey in Extreme North Province of Cameroon: Lessons Learned*. Center for Global Health Lecture. Denver, Colorado. May 2008.
210. *Risk Assessment in Glaucoma: Is it Useful?* East Coast Glaucoma Symposium. New York, New York. June 2008.
211. *Risk Assessment for Glaucoma: Is it Useful?* 12th Annual Ophthalmology Symposium, University of Colorado Denver, School of Medicine. Denver, Colorado. September 2008.
212. *The University Dimension of Academic Health Center Integration*. Association of Academic Health Centers 2008 Annual Meeting. Scottsdale, Arizona. October 2008.
213. *Intraocular Pressure: Does it Measure Up?* International Glaucoma Risk & Disease Management Symposium, The University of Toronto. Toronto, Ontario, Canada. October 2008.
214. *Healthcare Reform: Issues and Challenges*. Denver Eclectics. Denver, Colorado. February 2009.
215. *The Elimination of Racial and Ethnic Health Disparities*. Columbia University. New York, New York. February 2009.
216. *Meeting the Challenge of Preventing Blindness from Open-Angle Glaucoma in People of African Heritage*. World Glaucoma Congress. Boston, Massachusetts. July 2009.
217. *Maintaining Momentum in Challenging Economic Times: Strategic Decision Making to ARRA*. Association of Academic Health Centers. Chicago, Illinois. September 2009.
218. *Risk Factor: The Birth, The Evolution, and The Practice*. 13th Annual Ophthalmology Symposium, University of Colorado Denver, School of Medicine. Denver, Colorado. October 2009.
219. *Who Should We Be Treating? Lessons from Natural History Studies*. Glaucoma Subspecialty Day, American Academy of Ophthalmology. Chicago, Illinois. October 2010.
220. *Epidemiology of Eye Diseases*. American Academy of Ophthalmology Media Briefing. Chicago, Illinois. October 2010.
221. *Prevalence/Incidence of Open-Angle Glaucoma Worldwide*. World Glaucoma Congress. Paris, France. June 2011.
222. *Normal Tension Glaucoma: Different Disease Entity From Primary Open Angle Glaucoma?* World Glaucoma Congress. Paris, France. June 2011.

223. *Cultural Diversity and Healthcare: Defining Culture, Ethnicity, Race, and Its Impact on Attitudes About Healthcare and Wellness*. American Academy of Ophthalmology/Prevent Blindness America Symposium. Orlando, Florida. October 2011.
224. *Pearls and Perils of Navigating the Academic Career Ladder*. Network of Minority Research Investigators 10th Annual Workshop. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. April 2012.
225. *Diversifying the Biomedical Research Workforce*. 7th Annual Summer Meeting, Coalition of Urban Serving Universities and the Association of Public and Land-Grant Universities. Washington DC. June 2012.
226. *Collectively Meeting the Needs of a Diverse Population to Improve Oral Health*. A Joint Convention of the Hispanic Dental Association, the National Dental Association, and the Society of American Indian Dentists: Multi-Cultural Oral Health Summit. Boca Raton, Florida. July 2012.
227. *Pathways to Leadership in Health*. Leadership Plenary Speaker, Minority Faculty Career Development Seminar, Association of American Medical Schools (AAMC). Chicago, IL. September 2012.
228. *Addressing Diversity in the Research Workforce and Disparities in Palliative Care Studies*. Palliative Care Research Cooperative Group Investigator's Meeting. Denver, Colorado. September 2012.
229. *Why Should We Care About Health Disparities? The Role of Academic Medical Centers in Addressing Health Disparities Conference*. University of Pittsburgh School of Medicine. Pittsburgh, Pennsylvania. October 2012.
230. *Partnerships to Accelerate the Translation of Research into the Marketplace: New Opportunities and Challenges*. New Horizons Forum. San Francisco, California. February, 2013.

Named and Honorary Lectures

1. *Epidemiology of Eye Disorders Worldwide: Strategies for Prevention and Control*. Invited University Lecture, University of Colombo, Colombo. Sri Lanka. August 1995.
2. *Clinical Trials and Observational Studies: What Have We Learned?* Third Annual Roger P. Mason Memorial Lecture. Howard University. Washington DC. September 1996.
3. *Assessing the Optic Nerve with Confocal Laser Imaging Systems*. Keynote Address, All India Ophthalmology Society Conference. New Delhi, India. February 1997.
4. *Glaucoma Clinical Trials*. Roger P. Mason Memorial Lecture, National Medical Association. Honolulu, Hawaii. July 1997.
5. *How Glaucoma Affects the Quality of Life*. 18th Annual Janice Krushner Memorial Lecture, International Glaucoma Association. London, England. November 1999.
6. *Glaucoma: What's Race Got to Do with It?* Irving Leopold Lecture, 5th Annual Ocular Drug and Surgical Therapy Update. Dana Point. California. February 2002.

7. *What is Race and is it Relevant in Clinical Research.* Irving Leopold Honoree, Allergan Pharmaceuticals. Irvine, California. September 2003.
8. *Roles and Responsibilities of Academic Health Sciences Center.* John Aure Buessler Distinguished Lectureship, Texas Tech University Rawls College of Business. Lubbock, Texas. November 2003.
9. *A Perspective on Race and Glaucoma.* H. Saul Sugar Lectureship in Glaucoma, Henry Ford Hospital & Medical Centers 27th Annual Alumni Meeting. Dearborn, Michigan. June 2004.
10. *The Risk Factor and Glaucoma.* Claude Cowan Sr. Memorial Lecture, National Medical Association. New York, New York. July 2005.
11. *The Risk Factor: Past, Present, Future.* Keynote Lecture, Duke University Fall Glaucoma Symposium. Durham, North Carolina. September 2005.
12. *The Risk Factor and Glaucoma.* Konstantin Konstas Memorial Lecture, 39th Panhellenic Ophthalmological Congress. Thessaloniki, Greece. June 2006.
13. *1986-2006: Reflections on Glaucoma.* Keynote Lecture. 6th International Glaucoma Symposium of the International Glaucoma Society. Athens, Greece. March 2007.
14. *Young Scholars and the Importance of Mentoring.* Keynote Lecture. Colorado Conference of Minority Transportation Officials 2nd Annual Scholarship Banquet. Denver, Colorado. March 2007.
15. *1986-2006: Reflections on Glaucoma,* Philip Ellis Keynote Lecture. 11th Annual Ophthalmology Symposium, University of Colorado Denver School of Medicine. Denver, Colorado. October 2007.
16. *Risk Factor: The Concept, the Evolution, and the Practice.* American Glaucoma Society Keynote Lecture. Glaucoma 2007 Subspecialty Day, American Academy of Ophthalmology Annual Meeting. New Orleans, Louisiana. November 2007.
17. *The Elimination of Racial and Ethnic Health Disparities: Institutional Responses/Personal Reflections,* Alvin Poussaint Lecture. Harvard Medical School. Boston, Massachusetts. March 2008.
18. *Healthcare Reform: After Seven Decades, Are We There Yet?* Memorial Lecture of the Roman Barnes Society of Ophthalmology. San Francisco, California. October 2009.
19. *Reducing Health Disparities: Historical, Institutional, Personal Views.* Dean's Lecture. University of California, Davis. December 2009.
20. *1847-2010: Unfinished Business – Minorities in Medicine.* State of the Art Lecture, Society of Black Academic Surgeons. Durham, North Carolina. May 2010.
21. *Research Potential: Realized.* Keynote Lecture. 2012 STEM and Undergraduate Research Symposium. Albany State University. Albany, Georgia. October 2012.

Bibliography

Peer-reviewed Publications:

1. **Wilson MR**, Walker AM, Dueker DK, and Crick RP: Risk Factors for Rate of Progression of Glaucomatous Visual Field Loss: A Computer-Based Analysis. *Arch Ophthalmol* 100: 737-747, 1982.
2. **Wilson MR**, Richardson TM, Hertzmark E, and Grant WM: Race as a Risk Factor for Progressive Glaucomatous Damage. *Arch Ophthalmol* 17: 653-659, 1985.
3. **Wilson MR**, Hertzmark E, Walker AM, Childs K, Epstein DL: A Case-Control Study of Risk Factors in Open-Angle Glaucoma. *Arch Ophthalmol* 105: 1066-1071, 1987.
4. Singh G, **Wilson MR**, and Foster CS: Mitomycin Eye Drops as Treatment for Pterygium. *Ophthalmol* 95: 813-826, 1988.
5. **Wilson MR**, Lee DA, Yoshizumi MO, Martin W, Higginbotham EJ: Use of Intraocular Gas in Post-Filtration Surgery Flat Anterior Chamber. *Arch Ophthalmol* 106: 1345, 1988.
6. **Wilson MR**: Glaucoma in Blacks: Where Do We Go From Here? *JAMA* 261: 281, 1989.
7. Mason RP, Kosoko O, **Wilson MR**, et al: National Survey of the Prevalence and Risk Factors of Glaucoma in St. Lucia, West Indies. Part I: Prevalence Findings. *Ophthalmol* 96: 1363-1368, 1989.
8. **Wilson MR**: Posterior Lip Sclerectomy vs. Trabeculectomy in West Indian Blacks. *Arch Ophthalmol* 107: 1604-1608, 1989.
9. Singh G, **Wilson MR**, Foster CS: Long-term Follow-up Study of Mitomycin Eye Drops as Adjunctive Treatment for Pterygia and its Comparison with Conjunctival Autograft Transplantation. *Cornea* 9(4): 331-334, 1990.
10. Lee DA, **Wilson MR**, Yoshizumi MO, Hall M: The Ocular Toxicity of Gases When Injected into the Anterior Chamber of Rabbit Eyes. *Arch Ophthalmol* 109: 571-575, 1991.
11. **Wilson MR**, Lee DA, Baker RS, et al: The Effects of Topical Mitomycin on Glaucoma Filtering Surgery in Rabbits. *J Ocul Pharmacol* 7: 1-8, 1991.
12. Charles JB, Ganthier R, **Wilson MR**, et al: The Use of Biodegradable Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery. *Ophthalmol* 98: 503-508, 1991.
13. **Wilson MR**, Wooten F, and Williams J: Frequency and Characteristics of Ocular Trauma in an Urban Population. *J Natl Med Assoc* 83: 97-701, 1991.
14. **Wilson MR**: Primary Open-Angle Glaucoma: Magnitude of the Problem in the United States. *J Ocul Pharmacol* 1: 64-68, 1992.
15. **Wilson MR**: Ofloxacin Study Group: Ofloxacin vs. Tobramycin for the Treatment of External Ocular Infection. *Arch Ophthalmol* 110: 1234-1237, 1992.
16. Sanders R and **Wilson MR**: Diabetes Related Eye Disorders. *J Natl Med Assoc* 85: 104-108, 1993.
17. Drake M, **Wilson MR**, Harris D., Goodwin T: Levobunolol Compared to Dipivefrin in African American Patients With Open-Angle Glaucoma. *J Ocul Pharmacol* 9: 91-95, 1993.

18. **Wilson MR** and Baker RS: Prognostic Factors for Glaucoma Filtration Surgery. *J Ocul Pharmacol* 2: 223-226, 1993.
19. Sarraf D, Eezzuduemhoi D, Cheng Q, **Wilson MR**, Lee DA: Aqueous and Vitreous Concentration of Mitomycin-C by Topical Administration After Glaucoma Filtration Surgery. *Ophthalmol* 100: 1574-1579, 1993.
20. **Wilson MR**, Baker RS, Lee D, et al: Reproducibility of Postural Changes in Intraocular Pressure with the Tonopen and Pulsair Tonometers. *Am J Ophthalmol* 116: 479-483, 1993.
21. **Wilson MR**, Neumann R: Free Conjunctival Patch for Repair of Persistent Late Bleb Leak. *Am J Ophthalmol* 117: 569-574, 1994.
22. **Wilson MR**, Khanna S: The Value of Different Screening Techniques in Glaucoma. *Current Opinion in Ophthalmology* 5(11): 69-75, 1994.
23. **Wilson MR (ed)**: Glaucoma: The Common Pathway to Blindness. Proceedings of the 1993 AAO/NSPB Glaucoma Symposium. *J Glaucoma* 3: 165-183, 1994.
24. **Wilson MR**, Lee DA, Bourque L: Does the Public Understand the Differences Between Ophthalmologists and Optometrists? *Ophthalmic Epidemiology* 1: 121-129, 1994.
25. Coleman A, Hill D, **Wilson MR**, et al: Clinical Experience with the Ahmed Glaucoma Valve Implant. *Am J Ophthalmol* 120: 23-31, 1995.
26. Sponsel WE, Ritch R, Stamper R, Higginbotham E, Anderson DR, **Wilson MR**, Zimmerman T, for the Prevent Blindness America Glaucoma Advisory Committee: Prevent Blindness America Visual Field Screening Study. *Am J Ophthalmol* 120: 699-708, 1995.
27. Sponsel WE, Ritch R, Stamper R, Higginbotham EJ, Anderson DR, **Wilson MR**, Zimmerman TJ: Prevent Blindness America Visual Field Screening Study. *Am J Ophthalmol* 121: 590-591, 1996.
28. **Wilson MR**, Mansour M, Atud AE, et al: A Population-Based Study of Xerophthalmia in the Extreme North Province of Cameroon, West Africa. *Arch Ophthalmol.* 114: 464-468, 1996.
29. **Wilson MR**, Mansour M, Ross-Degnan D, et al: Prevalence and Causes of Low Vision and Blindness in the Extreme North Province of Cameroon, West Africa. *Ophthalmic Epidemiology* 3: 22-33, 1996.
30. **Wilson MR**, Gaasterland D: Translating Research into Practice: Controlled Clin Trials and Their Influence on Glaucoma Management. *J Glaucoma* 5: 139-146, 1996.
31. Baker RS, **Wilson MR**, Flowers CW, et al: A Population-Based Study of Severe Work-Related Ocular Injuries: Part 1. Age, Sex, Race Distributions. *Am J Ophthalmol* 122: 213-219, 1996.
32. Coleman AL, Smyth RJ, **Wilson MR**, Tam M: Initial Clinical Experience with the Ahmed Glaucoma Valve Implant in Pediatric Patients. *Arch Ophthalmol* 115: 186-193, 1997.

33. Coleman AL, Mondino BJ, **Wilson MR**: Clinical Experience with the Ahmed Glaucoma Valve Implant in Eyes with Prior or Concurrent Penetrating Keratoplasties. *Am J Ophthalmol* 123: 54-61, 1997.
34. Gutierrez PR, **Wilson MR**, Johnson C, et al: The Influence of Glaucomatous Visual Field Loss on Health-Related Quality of Life. *Arch Ophthalmol* 115: 777-784, 1997.
35. **Wilson MR**: The "Myth of 21". *J Glaucoma* 6: 75-77, 1997.
36. Baker RS, Watkins NL, **Wilson MR**, et al: Demographic and Clinical Characteristics of Patients with Diabetes Presenting to an Urban Hospital Ophthalmology Clinic. *Ophthalmol* Vol 123, No. 8:1373-1379, 1998.
37. Lee BL, Gutierrez P, Gordon M, **Wilson MR**, Cioffi GA, Ritch R, Sherwood M, Mangione C: The Glaucoma Symptom Scale GSS): A Brief Index of Glaucoma-Specific Symptoms. *Arch Ophthalmol* 116: 861-866, 1998.
38. **Wilson MR**, Coleman AL, Yu F, Bing EG, Sasaki IF, Berlin K, Winters J, Lai A: Functional Status and Well-Being in Patients with Glaucoma as Measured by the Medical Outcomes Study Short Form-36 Questionnaire. *Ophthalmol* 105: 2112-2116, 1998.
39. Baker RS, **Wilson MR**, Flowers CW, et al: A Population-Based Study of Severe Work-Related Ocular Injuries: Part II. Diagnoses, Causes, Resource Utilization, and Outcomes. *Ophthalmic Epidemiology* 6: 159-169, 1999.
40. Hamush NG, Coleman AL, **Wilson MR**: Ahmed Glaucoma Valve Implant for Management of Glaucoma in Sturge – Weber Syndrome. *Am J Ophthalmol* 128: 758-760, 1999.
41. Topouzis F, Coleman AL, Choplin N, Bethlem MM, Hill R, Yu F, Panek WC, **Wilson MR**: Follow-up of the Original Cohort with the Ahmed Glaucoma Valve Implant. *Am J Ophthalmol* 128: 198-204, 1999.
42. Bartlett JD, Olivier M, Richardson T, Whitaker R Jr, Pensyl D, **Wilson MR**: Central Nervous System and Plasma Lipid Profiles Associated with Carteolol and Timolol in Postmenopausal Black Women. *J Glaucoma* 8(6): 388-395, 1999
43. Lee BL, **Wilson, MR**(ed): Health Related Quality of Life in Cataract and Glaucoma. *J Glaucoma* 9: 87-94, 2000.
44. **Wilson MR**, Mendis U, Smith SD, Paliwal A: Ahmed Glaucoma Valve Implant vs Trabeculectomy in the Surgical Treatment of Glaucoma. A Randomized Clinical Trial. *Am J Ophthalmol* 130: 267-273, 2000.
45. **Wilson MR**, Coleman AL, Yu F, Sasaki IF, Bing EG, Kim MH: Depression in Patients with Glaucoma as Measured by Self Report Surveys. *Ophthalmol* 109:1018-1022, 2002.
46. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, **Wilson MR**, Kass MA: The Ocular Hypertension Treatment Study: Baseline Factors that Predict the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol* 120: 714-720, 2002.

47. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, **Wilson MR**, Gordon MO: The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma. *Arch Ophthalmol* 120: 701-713, 2002.
48. **Wilson, MR**: Progression of Visual Field Loss in Untreated Glaucoma Patients and Suspects in St. Lucia, West Indies. *Trans Am Ophthalmol Soc Vol* 100: 365-410, 2002.
49. **Wilson MR**, Kosoko S, Cowan C, et al.: Progression of Visual Fields in Untreated Glaucoma and Glaucoma Suspects in St. Lucia West Indies. *Am J. Ophthalmol* 134: 399-405, 2002.
50. **Wilson MR**: Normal Tension Glaucoma. *Acta Ophthalmologica Scandinavica Vol* 80: 9-11, 2002.
51. **Wilson MR**, Mendis U, Paliwal A, Haynatzka V: Long-term Follow-up of Primary Glaucoma Surgery With Ahmed Glaucoma Valve Implant Versus Trabeculectomy. *Am J Ophthalmol Vol* 136: 464-470, 2003.
52. Racette L, **Wilson MR**, Zangwill LM, Weinreb RN, Sample PA: Primary Open-Angle Glaucoma in Blacks: A Review. *Surv Ophthalmol Vol* 48: 295-313, 2003.
53. **Wilson MR**, Drake M, Brandt J. Management of Ocular Hypertension. *J Glaucoma Vol* 13: 81-83, 2004.
54. Gong G, Kosoko S, Haynatzki GR, **Wilson MR**. Genetic Dissection of Myocilin Glaucoma. *Human Molecular Genetics Vol* 13: 91-102, 2004.
55. Topouzis F, Coleman AL, Yu F, Mavroudis L, Anastasopoulos E, Koskosas A, Pappas Th, Dimitrakos S, **Wilson MR**. Sensitivity and Specificity of the 76-Suprathreshold Visual Field Test to Detect Eyes with Visual Field Defect by Humphrey Threshold Testing in a Population-based Setting: The Thessaloniki Eye Study. *Am J Ophthalmol Vol* 137: 420-425, 2004.
56. Varma R, Ying-Lai M, Francis BA, Nguyen B, Deneen J, **Wilson MR**, Azen SP and the LALES Group. Prevalence of Open-Angle Glaucoma and Ocular Hypertension in Latinos: The Los Angeles Latino Eye Study. *Ophthalmol* 111: 1439-1448, 2004.
57. Friedman DS, **Wilson MR**, Liebmann JM, Fechtner RD, Weinreb RN. An Evidence-based Assessment of Risk Factors for the Progression of Ocular Hypertension and Glaucoma. *Am J Ophthalmol* 138: S19-S31, 2004.
58. Weinreb RN, Friedman DS, Fechtner RD, Cioffi GA, Coleman AL, Girkin CA, Liebmann JM, Singh K, **Wilson MR**, Kannel WB. Risk Assessment in the Management of Patients with Ocular Hypertension. *Am J Ophthalmol* 138: 458-467, 2004.
59. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, **Wilson MR**, Kass MA and the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals. *Arch Ophthalmol* 122(6): 813-820, 2004.
60. Jonescu-Cuypers C, Harris A, **Wilson MR**, Kagemann L, Mavroudis L, Topouzis F, Coleman A. Reproducibility of the Heidelberg Retinal Flowmeter in Determining Low Perfusion Areas in Peripapillary Retina. *Brit J Ophthamol* 88: 1266-1269, 2004.

61. Topouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E, Dimitrakos S, **Wilson MR**. Risk of Sudden Visual Loss Following Filtration Surgery in End-Stage Glaucoma. *Am J Ophthalmol* 140 (4): 661-666, 2005.
62. Racette L, Boden C, Kleinhandler SL, Girkin CA, Liebmann JM, Zangwill LM, Medeiros F, Bowd C, Weinreb RN, **Wilson MR**, Sample PA. Differences in Visual Function and Optic Nerve Structure Between Healthy Eyes of Blacks and Whites. *Arch Ophthalmol* 123: 1547-1553, 2005.
63. **Wilson, MR**. Administration and Leadership of the Health Professions Partnership Initiative: A Medical School Administrator's Perspective. *Acad Med* 81 (6): S55-S57, 2006.
64. Gong G, Haynatzki G, Haynatzka V, Howell R, Kosoko-Lasaki S, Fu YX, Yu F, Gallagher JC, **Wilson MR**. Bone Mineral Density-Affecting Genes in Africans. *J Nat Med Assoc* 98 (7): 1102-1108, 2006.
65. Naeim A, Keeler EB., Gutierrez PR, **Wilson MR**, Reuben D, Mangione CM. Is cataract surgery cost-effective among older patients with a low predicted probability for improvement in reported visual functioning? *Medical Care* 44 (11): 982-989, 2006.
66. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Pappas T, **Wilson MR**. Association of blood pressure status with optic disc structure in non glaucoma subjects. *Am J Ophthalmol* 142 (1): 60-67, 2006.
67. Topouzis F, Coleman A, Harris A, Anastasopoulos E, Yu F, Koskosas A, Pappas T, Mavroudis L, **Wilson MR**. Prevalence of Age-related Macular Degeneration in Greece: The Thessaloniki Eye Study. *Am J Ophthalmol* 142 (6): 1076-1079, 2006.
68. Cooney R, Kosoko-Lasaki O, Slattery B, **Wilson MR**. Proximal Versus Distal Influences on Underrepresented Minority Students Pursuing Health Professional Careers. *J Natl Med Assoc* 98 (9): 1471-1475, 2006.
69. Kosoko-Lasaki O, Gong G, Haynatzki G, **Wilson MR**. Race, Ethnicity and Prevalence of Primary Open Angle Glaucoma. *J Nat Med Assoc* 98 (10): 1626-1629, 2006.
70. Gong G, Kosoko-Lasaki O, Haynatski G, Lynch HT, Lynch JA, **Wilson MR**. Inherited, Familial and Sporadic Primary Open-Angle Glaucoma. *J Natl Med Assoc* 99 (5): 559-563, 2007.
71. Mavroudis L, Harris A, Topouzis F, **Wilson MR**, Yu F, Anastasopoulos E, Koskosas A, Siesky B, Pappas T, Founti P, Coleman A. Reproducibility of Pixel-by-Pixel Analysis of Heidelberg Retinal Flowmetry Images: the Thessaloniki Eye Study. *Acta Ophthalmol Scand* 2007.
72. Topouzis F, **Wilson MR**, Harris A, Anastasopoulos E, Yu F, Mavroudis L, Pappas T, Koskosas A, Coleman A. Prevalence of Open-Angle Glaucoma in Greece: The Thessaloniki Eye Study. *Am J Ophthalmol* 144 (4): 511-519, 2007.
73. Topouzis F, Coleman A, Harris A, Koskosas A, Founti P, Yu F, Anastasopoulos E, Pappas T, **Wilson MR**. Factors associated with undiagnosed open-angle glaucoma: The Thessaloniki Eye Study. *Am J Ophthalmol* 145 (2): 327-335, 2007.

74. **Wilson MR**, Lee PP, Weinreb R, Lee BL, Singh K. A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part 1: Methodology and Design. *Am J Ophthalmol* 145(3): 570-574, 2008.
75. Singh K, Lee B, **Wilson MR**. A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part II: Results and Interpretation. *Am J Ophthalmol* 145(3): 575-581, 2008.
76. **Wilson MR**, Krugman R. The Changing Face of Academic Health Centers: A Path Forward. *Acad Med* 83(9): 855-60, 2008.
77. Sample P, Girkin C, Zangwill L, Jain S, Becerra L, Medeiros F, **Wilson MR**, et al: The African Descent and Glaucoma Evaluation Study (ADAGES): Design and Baseline Data. *Arch Ophthalmol* 127(9): 1136-1145, 2009.
78. Topouzis F, **Wilson MR**, Coleman A, Harris A, Yu F. Increased Likelihood of Glaucoma at the Same Screening Intraocular Pressure in Subjects with Pseudoexfoliation: The Thessaloniki Eye Study. *Am J Ophthalmol* 148: 606-613, 2009.
79. **Wilson MR**, Singh K. Intraocular Pressure: Does it Measure Up? *The Open Ophthalmology Journal* 3: 32-7, 2009.
80. Kass M, Gordon M, Gao F, Heuer D, Higginbotham E, Johnson C, Keltner J, Miller P, Parrish R, **Wilson MR**. Delaying Treatment of Ocular Hypertension: The Ocular Hypertension Treatment Study. *Arch Ophthalmol* 128: 276-287, 2010.
81. Anastasopoulos E, Topouzis F, **Wilson MR**, Harris A, Pappas T, Yu F, Koskosas A, Founti P, Coleman AL. Characteristics of Pseudoexfoliation in the Thessaloniki Eye Study. *J Glaucoma*. 2011 Mar; 20(3):160-6.
82. Topouzis F, **Wilson MR**, Harris A, et al: Risk Factors for Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma in the Thessaoloniki Eye Study. *Am J Ophthalmol* 2011, June 9 (Epub ahead of print).
83. Lerner SF, Singh K, Susanna R, **Wilson MR**, Lee BL, and Maul E: Glaucoma Management in Latin America. Results of a Rand-like Appropriateness Methodology Consensus for Primary Open-Angle Glaucoma in Latin America. *Am J Ophthalmol* 2012, May 24 (Epub ahead of print).
84. Anastasopoulos E, Kakoulidou A, Coleman A, Sinsheimer J, **Wilson MR**, Fei Y, Salonikiou A, Pappas T, Founti P, Lambropoulos A, Topouzis F: Association of Sequence Variation in the CX3CR1 Gene With Geographic Atrophy Age-Related Macular Degeneration in a Greek Population. *Curr Eye Res*. (In Press).
85. Topouzis F, **Wilson MR**, Harris A, Founti P, Yu F, Anastasopoulos E, PappasT, Koskosas A, Salonikiou A, Coleman A: Association of Open-Angle Glaucoma with Perfusion Pressure Status in the Thessaloniki Eye Study. *Am J Ophthalmol*. (In Press).
86. Zhang X, Bullard KM, Cotch MF, **Wilson MR**, RovnerB, McGwin G, Owsley C, Barker L, Crews J, Saaddine J: Depression and Vision Loss Are Associated in Persons Aged 20+ Years in the United States, NHANES 2005-2008. *Arch Ophthalmol*. (In Press).

Publications as Part of Ocular Hypertension Treatment Study Group (Member of Steering/Executive Committee):

87. Gordon MO, Kass MA for the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants. *Arch Ophthalmol* 117: 573-583, 1999.
88. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 118: 1187-1194, 2000.
89. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: Contralateral Effect of Topical β -Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 130: 441-553, 2000.
90. Brandt JD, Beiser JA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group: The Central Corneal Thickness in the Ocular Hypertension Treatment Study. *Ophthalmol* 108: 1779-1788, 2001.
91. Feuer WJ, Parrish RK, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group: The Ocular Hypertension Treatment Study: Reproducibility of Cup/Disk Ratio Measurements Over Time at an Optic Disc Reading Center. *Am J Ophthalmol* 133: 19-28, 2002.
92. Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Treatment Study Group: Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study. *Ophthalmol* 109: 432-437, 2002.
93. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group: Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 121: 643-650, 2003.
94. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group: Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 138: 717-722, 2004.
95. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Kirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Racial Differences in Optic Disc Topography: Baseline Results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 122: 22-28, 2004.
96. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study design and baseline factors. *Am J Ophthalmol* 137: 219-227, 2004.

97. Coleman A, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group: Baseline Risk Factors for the Development of POAG in the OHTS (Brief Report). *Am J Ophthalmol* 138: 684-685, 2004.
98. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication. *Am J Ophthalmol* 138: 717-22, 2004.
99. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study Group: Incorporating the Results of the Ocular Hypertension Treatment Study into Clinical Practice (Letter to the editor). *Arch Ophthalmol* 123: 1021-1022, 2005.
100. Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group: Normal Visual Field Test Results Following Glaucomatous Visual Field End Points in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 123: 1201-1206, 2005.
101. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. Baseline Topographic Optic Disc Measurements are Associated with the Development of Primary Open Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 123: 1188-97, 2005.
102. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vanderbroucke R, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Group: Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. *Am J Ophthalmol* 140: 762-64, 2005.
103. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group. Management of Ocular Hypertension: A Cost-effectiveness Approach from the Ocular Hypertension Treatment Study. *Am J Ophthalmol*. 141: 997-1008, 2006.
104. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study Group. Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci*. 47: 3896-3903, 2006.
105. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group (OHTS). The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the OHTS. *Ophthalmol*. 113: 1603-12, 2006.
106. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA. Topical Ocular Hypotensive Medication and Lens Opacification: Evidence from the Ocular Hypertension Treatment Study. *Am J Ophthalmol*. 142: 800-12, 2006.
107. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study Group. Detection and Prognostic Significance of Optic Disc Hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmol*. 113: 2137-43, 2006.

108. The Ocular Hypertension Treatment Study Group and European Glaucoma Prevention Study Group. A Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension. *Ophthalmol* 114: 10-19, 2007.
109. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study Group. Comparison of Initial Intraocular Pressure Response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in African Americans and Whites in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 125: 454-9, 2007.
110. Keltner JL, Johnson CA, Cello DK, Bandermann S, Fann JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study. *J Glaucoma* 16: 665-9, 2007.
111. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. Diabetes and Glaucoma. *Arch Ophthalmol* 126(5): 746-a-7, 2008.
112. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a History of Diabetes Mellitus Protective Against Developing Primary Open-Angle Glaucoma? *Arch Ophthalmol* 126: 280-2, 2008.
113. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension Treatment Study Group. Changes in Central Corneal Thickness Over Time: the Ocular Hypertension Treatment Study. *Ophthalmol* 115(9): 1550-1556, 2008.
114. Bhorade AM, Gordon MO, Wilson B, Weinrab RN, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group. Variability of intraocular pressure measurements in observation participants in the Ocular Hypertension Treatment Study. *Ophthalmol* 116: 717-724. 2009.
115. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO; Ocular Hypertension Treatment Study (OHTS) Group. The incidence of retinal vein occlusion in the ocular hypertension treatment study. *Ophthalmology* 117(3): 484-488, 2010.

Invited Commentaries and Articles:

1. **Wilson MR**, Reaves H: Additional Comments on the Effect of Triamcinolone Injection. *Arch Ophthalmol* 105: 1166, 1987.
2. **Wilson MR**: Hypotony in "Consultation Section." *J Cataract Refr Surg* Vol. 19, No. 6: 810-811, 1993.
3. **Wilson MR**, Weinreb R: Who Should Be Examined for Glaucoma? *Focus on Glaucoma* Vol. 7, No. 2. Spring 1993.
4. **Wilson MR**: Management of Iridocorneal Syndrome in "Cases in Controversy." *J Glaucoma* 3: 154-159, 1994.
5. **Wilson MR**: How Clinical Trials Could Change Glaucoma Treatment Patterns. *Review of Ophthalmology* September, 1997.
6. **Wilson MR**: Management of Late Bleb Leaks. *J Glaucoma* 8: 263-266, 1999.

7. **Wilson MR:** Epidemiology in Ophthalmology. Editorial. Arch Ophthalmol. 119:1374-1375, 2001.
8. **Wilson MR:** A New Role for Diode Laser Trans-Scleral Cyclophotocoagulation? Editorial. Arch Ophthalmol 119: 424-425, 2001.
9. **Wilson MR:** Racial Disparities in Vision Impairment and Blindness: Causes and Future Research Direction. Editorial. Ophthalmol 108:1719-1720, 2001.
10. **Wilson MR:** Screening Paradigms in Glaucoma. Invited Article for 10th Anniversary, J Glaucoma Sup 1, Vol 10: 5: S25-S27, 2001.
11. **Wilson MR:** A Need for Innovation in Glaucoma Surgery. Editorial. Arch Ophthalmol 120:633, 2002.
12. **Wilson MR.** Glaucoma in the Caribbean: Implications for the African American Population. Glaucoma Management News December 2002.
13. Lee BL and **Wilson MR:** The Ocular Hypertensive Treatment Study Commentary. Current Opinion in Ophthalmology 14:74-77, 2003.
14. Lee BL and **Wilson MR:** Randomized Controlled Trials in Glaucoma. Glaucoma Perspectives in Practice 51:1-8, 2003.
15. **Wilson MR** and Brandt JD: Update on Glaucoma Clinical Trials. American Academy of Ophthalmology, Focal Points Vol 21: 9: 1-9, 2003.
16. **Wilson MR:** The Use of “Race” for Classification in Medicine: Is it Valid? Editorial. J Glaucoma 12:293-294, 2003.
17. **Wilson MR:** NNT. Treatment of Ocular Hypertension and Early Glaucoma: How Much Benefit and is it Worth the Cost? Editorial. International Glaucoma, Review Vol 5:1: 10, 2003.
18. **Wilson MR:** New Evidence, New Treatments: The Impact of NEI Clinical Trials on Glaucoma Management. Review of Ophthalmology November 2003.
19. **Wilson MR:** Discussion of paper: Racial Differences in Optic Disc Topography: Baseline Results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. International Glaucoma Review, Volume 6-1, 2004.
20. **Wilson MR.** Discussion of paper: Prevalence of Open Angle Glaucoma in Rural South Indian Population. International Glaucoma Review, Volume 7-3, 2006.

Book Chapters:

1. **Wilson MR:** Epidemiologic Aspects of Glaucoma. International Ophthalmology Clinics, Little Brown and Co., Boston, MA. Vol. 30, No. 3:153-160, 1990.
2. **Wilson MR:** Glaucoma in Blacks. Mediguide to Special Problems in Ophthalmology. Dellacorte Publications Inc., New York. Vol 1, Issue 1, 1991

3. **Wilson MR** and Drake MV: Glaucoma in Blacks: Epidemiology and Management. Clinical Signs in Ophthalmology. Mosby-Year Book, Inc., St. Louis, MO. Vol XIII, No. 2, 1992.
4. **Wilson MR**: Epidemiology of Glaucoma. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology. W.B. Sanders Co., Philadelphia, PA. Chapter 110: 1275-1284, 1994.
5. **Wilson MR**: Peripheral Iridectomy and Chamber Deepening. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology. W.B. Sanders Co., Philadelphia, PA. Chapter 142: 1618-1622, 1994.
6. **Wilson MR**: Glaucoma. Epidemiology and Risk Factors. In Higginbotham EJ, Lee DA, eds. Management of Difficult Glaucomas: A Clinician's Guide. Blackwell Scientific Publications, Cambridge, Mass. Chapter 1: 3-8, 1994.
7. **Wilson MR** and Bacharach J: Glaucoma. In Rakel RE, ed. Conn's Current Therapy. W.B. Saunders Co., Philadelphia, PA. Section 13: 915-918, 1994.
8. **Wilson MR** and Martone J: The Epidemiology of Chronic Open-Angle Glaucoma and Ocular Hypertension. In Ritch R, Shields MB, Krupin T, eds. The Glaucomas. A Multi-Volume Reference. Mosby Year Book, St. Louis. Chapter 35: 753-768, 1996.
9. **Wilson MR**: The Epidemiology of Glaucoma. In Epstein DA, ed. Chandler and Grant's Glaucoma. Lea and Febiger, London. Part 11: Chapter 72: 641-647, 1996.
10. **Wilson MR**: Epidemiology of Glaucoma. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology 2nd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 1, Chapter 28: 531-537, 1999.
11. **Wilson MR**: Incisional Surgical Techniques for Angle Closure Glaucoma. In Albert DM, Jakobiec FA, eds. Principles and Practices of Ophthalmology, 2nd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 4, Chapter 225: 2954 - 2958, 1999.
12. Coleman A, **Wilson MR**: Risk Factor Assessment and Glaucoma Screening. Ophthalmology Clinics of North America. W.B. Saunders Co., Philadelphia, PA. Volume 13, Number 3: 349 -360, 2000.
13. **Wilson MR**: Primary Open-Angle Glaucoma and Risk Factors. In Higginbotham EJ, Lee DA, eds. Clinical Guide to Glaucoma Management. Butterworth-Heinemann, MA. 3-9, 2004.
14. Brandt JD and **Wilson MR**: What Have We Learned from the Major Glaucoma Clinical Trials? In Krieglstein GK and Weinreb RN, (series eds.) and Grehn F and Stamper R, (vol. eds.). Essentials in Ophthalmology: Vol. 1. Glaucoma, 1st Edition: 125-137. New York: Springer-Verlag, 2004.
15. **Wilson MR**: What is Race? International Ophthalmology Clinics, Little Brown and Co., Boston MA. Volume 43(4):1-8., 2003.
16. **Wilson MR** and Eezzuduemhoi DR: Ophthalmologic Disorders in Minority Populations. Medical Clinics of North America. W.B. Saunders Co, Philadelphia, PA. Volume 89, Issue 4: 795-804, July 2005.

17. Coleman A, Mansberger S, **Wilson MR**: Epidemiology of Primary Open-Angle Glaucoma. Principles and Practices of Ophthalmology, 3rd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 1, Chapter 36: 395-402, 2008.
18. **Wilson MR**, Gallardo M: Laser and Surgery Treatment of Angle-Closure Glaucoma. Principles and Practices of Ophthalmology, 3rd Edition. W.B. Sanders Co., Philadelphia, PA. Volume 2, Chapter 219: 2811-2820, 2008.
19. **Wilson MR**, Gamble V: The Role of Academic Medical Centers in the Elimination of Racial and Ethnic Health Disparities. Cultural Proficiency in Addressing Health Disparities. Jones and Bartlett Publishers. Sudbury, MA. Chapter 4: 73-82, 2009.
20. **Wilson MR**, Gallardo M: Risk Factors: Ethnicity and Glaucoma. In Schacknow P, Samples J (eds). The Glaucoma Book. Springer, Heidelberg, Germany. Chapter 10: 101-109, 2010.
21. **Wilson MR**, Kahook M: Medical Treatment: Treated and Untreated Glaucoma and Ocular Hypertension. Pearls of Glaucoma Management. Springer-Verlag Berlin Heidelberg. Chapter 29: 225-230, 2010.
22. Horsley M, **Wilson MR**: The Epidemiology of Glaucoma. Chandler and Grant's Glaucoma. (In Press)
23. Ibrahim AM, **Wilson MR**. Foreword. In Steven A. Wartman (ed). Confluence of Policy and Leadership in Academic Health Science Centers: A Professional and Personal Guide. Radcliffe Publishing, Ashland, Ohio. Pages v-x, 2012.

Books:

1. **Wilson MR**, Martone JF (eds). The Lighthouse Handbook on Vision Impairment and Vision Rehabilitation. Part 1, Visual Disorders: The Medical Perspective. Oxford University Press, New York, New York, 2000.

Thesis and Monographs:

1. **Wilson MR**: Eye Care Survey in Los Angeles County. Thesis for Master of Science in Epidemiology. UCLA, 1990.
2. **Wilson MR**: Low Vision and Vitamin A Deficiency in the Extreme North Province of Cameroon. Monograph Prepared for Nutrition Service, Cameroon Ministry of Health and the Vitamin A Field Support Project, International Science and Technology Institute, August, 1993
3. **Wilson, MR**: St. Lucia Follow-up Study: Progression of Visual Field in Untreated Glaucoma and Glaucoma Suspects. Thesis for Trans. Am. Ophthalmol. Soc. Vol. 100, 2002.

Reports and Monographs (as part of writing committee):

1. AAO Basic and Clinical Science Course, Section 15: Glaucoma, 1999-2000 and 2000-2001.
2. Visual Impairments: Determining Eligibility for Social Security Benefits. National Research Council. Editors Peter Lennie and Susan B. VanHemel. National Academy Press 2002.

3. Academic Health Centers: Leading Change in the 21st Century. Institute of Medicine. National Academy Press 2003.
4. Screening for Open-Angle Glaucoma: Where Are We Now and Where To From Here? Report from the Global AIGS Committee on Screening for Open Angle Glaucoma. International Glaucoma Review, Volume 7-3, 2006.
5. Code Red: The Critical Condition of Health in Texas. Report from the Task Force on Access to Health Care in Texas. April, 2006.
6. Changing Perspectives on Eye Health. November, 2006.
7. Geographic Adjustment in Medicare Payment. Phase 1: Improving Accuracy. Institute of Medicine. National Academy Press 2011.
8. Geographic Adjustment in Medicare Payment. Phase II: Implications for Access, Quality, and Efficiency. Institute of Medicine. National Academy Press 2012.

Letters and Comments:

1. **Wilson MR:** Efficacy and Complications of Full-thickness Filters. Letter to the Editor. J Glaucoma 2: 75, 1993.
2. **Wilson MR:** Laser Treatment May Halt Neovascular Glaucoma Progression. Ophthalmol Times 17(16): 13, 1994 (Passim).
3. **Wilson MR:** Vision Loss in the Glaucoma Population: Magnitude and Race. J Glaucoma 1: 219, 1992.
4. **Wilson MR:** Mitomycin Trabeculectomy: Clinical Precautions. JSEI-UCLA Clinical Update 3(1): 2-4, 1994 (Passim).
5. Baker RS, Flowers CW, Casey R, Fong D, and **Wilson MR:** Efficacy of ofloxacin vs. cefazolin and Tobramycin in the Therapy for Bacterial Keratitis. Letter to the Editor. Arch Ophthalmol 114: 632, 1996.
6. **Wilson MR:** Glaucoma in Blacks: Unraveling the Web of Physiologic, Genetic, Socioeconomic Factors. Ocular Surgery News Vol. 15: (10) 1997 (Passim).
7. Jack S, **Wilson MR:** Optic Disc Hemorrhages and Glaucoma. Letter to the Editor. Ophthalmol 104: 566, 1997.
8. Ali B, **Wilson MR:** Ciliary Body Endophotocoagulation during Pars Plana Vitrectomy in Eyes with Vitreoretinal Disorders and Concomitant Uncontrolled Glaucoma. Letter to the Editor. Ophthalmol 104: 733, 1997.
9. **Wilson MR:** Medical Ethics Issues Devolve to Individuals. Opinion–Editorial. Omaha World Herald December 2, 1999.
10. **Wilson MR.** Texas Tech University Health Sciences Center’s Long-range Goal is to Make Lubbock the ‘Healthiest City in Texas’. Editorial. Lubbock Avalanche Journal September 28, 2003.

11. **Wilson MR.** OAG in the Visual Impairment Project. Letter to the Editor. *Ophthalmol* 111: 197, 2004.
12. **Wilson MR.** Make Healthy Choices When It's Time to Slake Your Thirst. Opinion-Editorial. *Lubbock Avalanche Journal* June 8, 2004.
13. **Wilson MR.** Health Sciences Center Celebrating 35 years of Service to West Texas. Opinion-Editorial. *Lubbock Avalanche Journal* November 27, 2004.
14. **Wilson MR.** Tuition Deregulation Formula Does Not Benefit Tech Health Sciences Center. Opinion-Editorial. *Lubbock Avalanche Journal* January 8, 2005.
15. **Wilson MR.** Where Tuition Deregulation Falls Short. Opinion-Editorial. *Odessa American* January 19, 2005.
16. **Wilson MR.** A Simple Glaucoma Exam Can Prevent Blindness. Opinion-Editorial. *Southwest Digest* January 20, 2005.
17. **Wilson MR.** Does Tuition Deregulation Really Help Medical Schools. Opinion-Editorial. *Amarillo Globe News* January 23, 2005.
18. **Wilson MR.** Health Science Centers Need New Revenue to Meet Needs of Texas. Opinion-Editorial. *El Paso Times* January 23, 2005.
19. **Wilson MR.** HSC Becoming Recognized Leader in the Health Disparities Research Area. Opinion-Editorial. *Lubbock Avalanche Journal* February 19, 2005.
20. **Wilson MR.** Faculty Vital to Tech, Thomason. Opinion-Editorial. *El Paso Times* February 27, 2005.
21. **Wilson MR.** Get Mom, Dad off the Bench. Opinion-Editorial. *Lubbock Avalanche Journal* March 1, 2005.
22. **Wilson MR.** Cutting-Edge Research Vital Component to Texas Tech HSC's Research Mission. Opinion-Editorial. *Lubbock Avalanche Journal* April 2, 2005.
23. **Wilson MR.** Health Sciences Center Students Represent Best of Tomorrow's Health Care Professionals. Opinion-Editorial. *Lubbock Avalanche Journal* May 14, 2005.
24. **Wilson MR.** Scholarships for Disadvantaged Students Bring Diversity to Health Care Profession. Opinion-Editorial. *Lubbock Avalanche Journal* June 25, 2005.
25. **Wilson MR.** Building a Better HSC. Opinion-Editorial. *Lubbock Avalanche Journal* September 17, 2005.
26. **Wilson MR.** TTU Health Science's Center's Mission Key to Fulfilling the Institution's Vision. Opinion-Editorial. *Lubbock Avalanche Journal* October 29, 2005.
27. **Wilson MR.** TTUHSC's Efforts to Increase Diversity Will Result in Better Health Care for All. Opinion-Editorial. *Lubbock Avalanche Journal* December 10, 2005.

28. **Wilson MR.** Funding for Area Health Education Centers Vital to Future of West Texans' Health Care. Opinion-Editorial. Lubbock Avalanche Journal January 21, 2006.
29. **Wilson MR.** TTUHSC Continues to Make Inroads in Addressing Work Force Shortages. Opinion-Editorial. Lubbock Avalanche Journal March 4, 2006.
30. **Wilson MR.** Glaucoma Can Steal Eyesight Before Diagnosis. Health Column. Lubbock Avalanche Journal March 9, 2006.
31. Racette L, Boden C, Kleinhandler S, Girkin C, Liebmann J, Zangwill L, Medeiros F, Bowd C, Weinreb R, **Wilson M**, Sample P. Optic Nerve Structure in Healthy Eyes: Author Reply. Arch Ophthalmol. Arch Ophthalmol 124:1508-9, 2006
32. **Wilson MR.** Regional Research Initiative Established at Texas Tech HSC for Study of Cancer. Lubbock Avalanche Journal April 15, 2006.
33. **Wilson MR.** TTU Health Sciences Center Grads Embark on Life of Service to Others. Lubbock Avalanche Journal May 27, 2006.
34. **Wilson MR.** Health Campus in Agony – CU Underfunded by any Reckoning. Opinion – Editorial. The Denver Post November 19, 2006.

Book Reviews:

1. **Wilson MR:** Glaucoma, edited by James McAllister and Richard P. Wilson. Arch Ophthalmol 108: 183-84, 1990.
2. **Wilson MR:** Breaking the Color Line in Medicine: African Americans in Ophthalmology, edited by Lenworth Johnson and OC. Bobby Daniels. Arch Ophthalmol. 121: 586, 2003.

Videos and CD ROMS:

1. Berlin RS, Cantor LB, Hodapp EA, Lee DA, **Wilson MR.** Glaucoma Basic and Clinical Science Course: What you need to know. National Audio Video, 1995; v 125-44 (October 30): A,B.
2. Fechtner R, Parrish R, Budenz D, Heuer D, Higginbotham E, **Wilson MR.** The Ocular Hypertension Treatment Study: Translating Evidence into Practice. Sept. 2002.
3. Glaucoma and You. Video prepared by Pfizer, American Academy of Ophthalmology and Institute of Church Administration and Management featuring Willie Mays, Diahann Carroll, and Drs. Eve Higginbotham, Kevin Greenidge, and **M. Roy Wilson.**

Abstracts:

1. **Wilson MR,** Hertzmark E, Walker AM, et al: Risk Factors for Primary Open-Angle Glaucoma: A Case-Control Study. Invest Ophthal Vis Sci 26(Suppl), 1985.
2. Maynard K, **Wilson MR,** and Richardson TM: The Effect of Colchicine and Cytochalasin B on the Attachment and Spreading of TM Cells In Vitro. Invest Ophthal Vis Sci 26(Suppl), 1985.

3. Wooten F, Singh G, Foster CS, and **Wilson MR**: Role of Endothelium in Non-healing Corneal Ulcers and Recurrent Epithelial Defects. Invest Ophthal Vis Sci 28(Suppl): 2, 1987.
4. Singh G, **Wilson MR**, Foster CS: Mitomycin Eye Drops as Treatment for Pterygium. Supplement to Ophthalmology, October 1987.
5. Mason RP, Kosoko O, Martone J, Cowan CL, Gear J, Ross-Degnan D, **Wilson MR**: National Survey of the Prevalence and Risk Factors of Glaucoma in St. Lucia, West Indies. Supplement to Ophthalmology, October 1987.
6. **Wilson MR**, Lee DA, Yoshizumi MO, Hall M, Singh G, and Salem F: Ocular Toxicity of Substances Injected into the Anterior Chamber of Rabbit eyes. Invest Ophthal Vis Sci 29(Suppl): 18, 1988.
7. Goodwin LT and **Wilson MR**: Posterior Lip Sclerectomy vs. Trabeculectomy in a Black Population. Invest Ophthal Vis Sci 29(Suppl): 367, 1988.
8. Mason RP, Kosoko O, Martone J, Cowan CL, **Wilson MR**, Gear J, Ross-Degnan D: Glaucoma Prevalence Survey in Saint Lucia, West Indies. Invest Ophthal Vis Sci 29(Suppl): 61, 1988.
9. Singh G, **Wilson MR**, Foster CS: Mitomycin Eye Drops as Adjunctive Treatment for Pterygia: Long-term Follow-up and Comparison with Conjunctival Autograft Transplantation. Supplement to Ophthalmology, October 1988.
10. Singh G and **Wilson MR**: Selective Suture Cutting to Control Corneal Astigmatism After Cataract Surgery. CLAO, New Orleans, January 18-22, 1989.
11. Singh G, **Wilson MR**, Foster CS: Mitomycin Eye Drops: A New Adjunctive Treatment for Pterygium (Poster). CLAO, New Orleans, January 1989.
12. Ganthier R, **Wilson MR**, Anders M, Scott TV, Reaves H, and Wooten F: Three-Year Efficacy of Argon Laser Trabeculoplasty in a Black Population. Invest Ophthal Vis Sci 30(Suppl): 352, 1989.
13. Goodwin T, **Wilson MR**, Lee DA, Wooten F, Glasgow B: The Effects of Topical Mitomycin C on Filtration Surgery in Rabbits. Invest Ophthal Vis Sci 30(Suppl): 417, 1989.
14. Singh G, **Wilson MR**, and Foster CS: Effectivity and Late Complications of Mitomycin in Treatment of Pterygium. Supplement to Ophthalmology. November 1989.
15. Sanford R, Gables C, Stewart R, Laibovitz R, Buka T, Long D, **Wilson MR**, and Moore V: A Clinical Comparison of the Fluoroquinolone Ofloxacin with Tobramycin and Gentamycin in the Treatment of External Ocular Infection. Supplement to Ophthalmology. November 1989.
16. **Wilson MR**, Sharma M, and Gueno W: Comparison of Henson Keeler Screening Visual Fields with Humphrey Threshold Visual Fields. Invest Ophthalmol Vis Sci 31(Suppl): 16, 1990.
17. Wooten F, **Wilson MR**, and Williams J: Frequency and Characteristics of Ocular Trauma in an Urban Population. Invest Ophthalmol Vis Sci 31(Suppl): 19, 1990.

18. Ganthier R, Charles JB, **Wilson MR**, Lee DA, et al: The Use of Biodegradable Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci 31(Suppl): 2, 1990.
19. O'Neal TD, **Wilson MR**: Glaucoma Prevalence in a Hispanic Population. Invest Ophthalmol Vis Sci 31(Suppl): 13, 1990.
20. Martone JF, Sponsel WE, Brady MA, **Wilson MR**, et al: Visual Field Screening in a West Indian Black Population Using Humphrey 30-2 and Henson CFS 2000 Perimetry. Invest Ophthalmol Vis Sci 31(Suppl): 432, 1990.
21. **Wilson MR**, Baker RS: Epidemiology of Myopia. Fourth International Conference on Myopia. Myopia International Research Foundation, 1990.
22. **Wilson MR**: Eye Care Survey in Los Angeles County. Journal of the Association for Academic Minority Physicians. Vol I, No. III: 102, 1990.
23. **Wilson MR**, Lee DA, Bourque L, Ingles S: A Population-Based Survey of the Public's Knowledge of Differences Between Eye Care Providers. Invest Ophthalmol Vis Sci. 32(Suppl): 1154, 1991.
24. Watkins NL, Baker RS, **Wilson MR**: Demographic and Clinical Characteristics of Diabetic Patients Presenting to an Urban Hospital Ophthalmology Clinic. Invest Ophthalmol Vis Sci 32(Suppl): 1142, 1991.
25. Baker RS, **Wilson MR**, Flowers C: Ophthalmic Information in Primary Care (Non-Ophthalmic) Journals. Invest Ophthalmol Vis Sci 32(Suppl): 1155, 1991.
26. Harris DY, Baker RS, Lee DA, **Wilson MR**: A Population-based Incidence Study of Severe Ocular Trauma. Invest Ophthalmol Vis Sci. 32(Suppl): 1122, 1991.
27. **Wilson MR**, Baker RS, Lee DA, Wheeler N: A Population-based Study of Severe Ocular Trauma from Assaults. Invest Ophthalmol Vis Sci 33(Suppl): 782, 1992.
28. Mohammadi P, Baker RS, **Wilson MR**: Evaluation of Postural Changes in Intraocular Pressure with the Tonopen and Pulsair Tonometers. Invest Ophthalmol Vis Sci 33(Suppl): 733, 1992.
29. Flowers CW, Baker RS, **Wilson MR**: Severe Work-Related Ocular Injuries: A Population-based Study. Invest Ophthalmol Vis Sci 33(Suppl): 781, 1992.
30. Fong I, Baker RS, **Wilson MR**, Lee DA: Population-based Study of Enucleation, Evisceration and Exenteration. Invest Ophthalmol Vis Sci 33(Suppl): 784, 1992.
31. Baker RS, Casey R, Lee DA, **Wilson MR**: Epidemiology of Penetrating Keratoplasty. Invest Ophthalmol Vis Sci 33(Suppl): 1211, 1992.
32. Syrquin MG, Baker RS, **Wilson MR**, Lee DA: A Population-based Epidemiologic Study of Pars Plana Vitrectomy. Invest Ophthalmol Vis Sci 33(Suppl): 1323, 1992.
33. Baker RS, **Wilson MR**: Severe Ocular Trauma: A Population-based Incidence Study for the State of California. Second International Symposium on Ocular Trauma. Geneva, Switzerland, 1992.

34. **Wilson MR**: Blebs: Prognostic Factors for Survival and Influencing Its Function. *Experimental Eye Research*. Vol 55, Supplement 1: 14, 1992.
35. **Wilson MR**, Martone J, Mansour M, et al: A Population-based Survey of Low Vision and Blindness in Cameroon, West Africa: Prevalence, Causes, and Risk Factors. *Invest Ophthalmol Vis Sci* 34(Suppl): 1294, 1993.
36. Baker RS, **Wilson MR**, Lee DA, et al: The Epidemiology of Endophthalmitis: A Statewide Population-based Survey. *Invest Ophthalmol Vis Sci* 34(Suppl): 1260, 1993.
37. Eezzuduemhoi RD, Sarraf D, **Wilson MR**, et al: Aqueous and Vitreous Concentrations of Mitomycin Following Topical Administration. *Invest Ophthalmol Vis Sci* 34(Suppl): 726, 1993.
38. Dang Y, Baker RS, **Wilson MR**, et al: Pediatric Ocular Trauma: A Statewide Population-based Survey. *Invest Ophthalmol Vis Sci* 34(Suppl): 2026, 1993.
39. Casey R, **Wilson MR**, Mansour M, et al: Nutritional, Biochemical, and Clinical Assessment of Vitamin A Deficiency in Cameroon, West Africa. *Invest Ophthalmol Vis Sci* 34(Suppl): 2918, 1993.
40. Bacharach J, Lee DA, Coleman A, et al: Non-Contact Transcleral Nd: YAG Laser Cyclophotocoagulation: Midterm Report. *Invest Ophthalmol Vis Sci* 34(Suppl): 739, 1993.
41. Atina EA, **Wilson MR**, Vitamin A Field Support Project (VITAL): Prevalence of Xerophthalmia and Risk of Vitamin A Deficiency Among Children in the Extreme North Province of Cameroon. IVACG Conference. Proceedings of the International Vitamin A Consultative Group, 1993.
42. **Wilson MR**, Khanna S, Baker R: Visual Field Defects in Diabetic Patients With Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci* 35(Suppl): 4286, 1994.
43. Khanna S, Baker R, **Wilson MR**: Pattern of Early Visual Field Loss in Patients with Low Tension Glaucoma. *Invest Ophthalmol Vis Sci* 35(Suppl): 2708, 1994.
44. Syrquin M, Baker R, Ali B, et al: The Influence of Prenatal Care Upon the Risk of Retinopathy of Prematurity in High Risk Infants. *Invest Ophthalmol Vis Sci* 35(Suppl): 1268, 1994.
45. Tam M, Choplin N, Coleman A, et al: Preliminary Results of Glaucoma Valve Implant Clinical Trial. *Invest Ophthalmol Vis Sci* 35(Suppl): 3048, 1994.
46. Smyth R, Tam M, Coleman A, et al: Pediatric Glaucoma Valve Implantation. *Invest Ophthalmol Vis Sci* 35(Suppl): 777, 1994.
47. Khanna S, Flowers C, Coleman A, Baker RS, **Wilson MR**: Grading Glaucomatous Field Defects. Observer Variability of the Aulhorn-Kalmayer Classification. *Invest Ophthalmol Vis Sci* 36 (Suppl): 1584, 1995.
48. March GA, Goldberg RA, Scott CT, Baker RS, Khanna S, Casey R, **Wilson MR**: Factors Associated with Delayed Discovery of Intraorbital Foreign Bodies. *Invest Ophthalmol Vis Sci* 36 (Suppl): 2357, 1995.

49. Scott CT, Baker RS, March GA, Dang YP, **Wilson MR**: Factors Associated with Delayed Presentation in an Urban Pediatric Eye Clinic. *Invest Ophthalmol Vis Sci* 36(Suppl): 365,1995.
50. Khanna S, Ali B, Chandramohan S, Brown SP, Coleman A, Baker RS, **Wilson MR**: Glaucomatous Field Defects. Validity of Subjective Aulhorn-Kalmayer Classification. *Invest Ophthalmol Vis Sci* 37(Suppl): 2315, 1996.
51. Chandramohan S, Khanna S, Ali B, Coleman A, Baker RS, **Wilson MR**: Comparison of Normative versus Non-normative based Methodology of Visual Field Analysis. *Invest Ophthalmol Vis Sci* 37 (Suppl): 2318, 1996.
52. Gutierrez PR, Mangione CM, **Wilson MR**: Relationship Between Visual Field Loss and Vision-Specific Quality of Life. *Invest Ophthalmol Vis Sci* 37(Suppl): 2981, 1996.
53. Baker RS, Flowers C, Casey, R, Fong, D, **Wilson MR**: Efficacy of Ofloxacin vs. Cefazolin and Tobramycin in the Therapy for Bacterial Keratitis. *Arch Ophthalmol*. 114: 632, 1996.
54. Gutierrez PR, Mangione CM, Gordon M, Cioffi R, Ritch R, Sherwood M, **Wilson MR**: The Effect of Glaucoma-Specific Symptoms and Functioning on Vision-Targeted Health-Related Quality of Life. *Invest Ophthalmol Vis Sci* 38(Suppl): 729, 1997.
55. Lee BI, Mangione CM, Gutierrez M, Gordon M, Cioffi GA, Ritch R, Sherwood M, **Wilson MR**: Reliability and Validity of a Survey to Assess Glaucoma-Specific Symptoms and Functional Limitations. *Invest Ophthalmol Vis. Sci* 38(Suppl): 826, 1997.
56. **Wilson MR**, Winters J, Yu F, Bing EG, Sasaki I: Quality of Life Among Patients with Eye Disease. *Invest Ophthalmol Vis Sci* 38(Suppl): 840, 1997.
57. Bing EG, Winters J, Yu F, **Wilson MR**, Sasaki I, Coleman AL: Depression in Patients with Eye Disease. *Invest Ophthalmol Vis Sci* 38(Suppl): 840, 1997
58. Ali B, Flowers C, Sharza S, **Wilson MR**, Baker RS: Prevalence of Ophthalmology Related Literature in Primary Care. *Invest Ophthalmol Vis Sci* 38(Suppl): 844, 1997.
59. Topouzis F, Yu F, Coleman AL, **Wilson MR**: The Risk of Complications After Cyclodestruction Versus Drainage Device Surgery. *Invest Ophthalmol Vis. Sci* 39(Suppl): 4077, 1998
60. Kosoko OB, **Wilson MR**, Copeland RA, Cowan CL, Enger C: Glaucoma Survey in St. Lucia, West Indies: Follow-up study. *Invest Ophthalmol Vis Sci* 40(Suppl): 929,1999.
61. Kosoko OB, **Wilson MR**, Copeland RA, Cowan CL, Enger C: Glaucoma Survey in St. Lucia, West Indies: International Agency for the Prevention of Blindness: Sixth General Assembly, Beijing, China, 1999
62. Thessaloniki Eye Study: Sita Versus 76 Suprathreshold (76 STHR) Visual Fields as Screening Tests in a Population Based Study. *Invest Ophthalmol Vis Sci* 41(Suppl): 1549, 2000.
63. Coleman AL, Topouzis F, Yu F, Mavroudis L, Tsina E, Tzetzzi D, Stango NT, **Wilson MR**: The Reliability of 76 Suprathreshold (76-ST) Visual Fields As Screening Tests in a Population-Based Study. European Glaucoma Society Millennium Meeting, London, England, 2000.

64. **Wilson MR**, Coleman AL, Sasaki IF, Yu F, Ellingsen KL: Depression In Glaucoma Patients. European Glaucoma Society Millennium Meeting, London, England, 2000.
65. Mavroudis L, Harris A, Topouzis F, Kagemann L, Yu F, Lalloos N, Stangos NT, **Wilson MR**: Reproducibility Of the Heidelberg Retinal Flowmeter in Determining Low Perfusion Areas in Peripapillary Retina. Invest Ophthalmol Vis Sci 42(Suppl): 1143, 2001.
66. Anastasopoulos E, Topouzis F, Yu F, Jonescu-Cuypers C, Harris A, Mavroudis L, Kagemann L, **Wilson MR**, Stangos N, Coleman A: Normative Topographic Optic Disk Parameters as Measured with the Heidelberg Retina Tomograph (HRT) in Eyes of a Population-Based Sample of Non-Glaucomatous Elderly People. Invest Ophthalmol Vis Sci (Suppl): 266, 2002.
67. Racette L, Boden C, Girkin C, Liebmann J, Zangwill I, Bowd Cm, Weinreb R, **Wilson MR**, Sample P: Visual Function and Optic Nerve Structure in African Americans with Healthy Eyes. Invest Ophthalmol Vis Sci (Suppl): 2125, 2002.
68. Mavroudis L, Harris A., Coleman A, Topouzis F, Yu F, Kagemann L, Anastasopoulos E, Koskosas A, Stangos N, **Wilson MR**: Distribution of Areas of Low Flow in the Retinal Peripapillary Blood Flow of Elderly Population. Invest Ophthalmol Vis Sci (Suppl): 2619, 2002.
69. Mavroudis L, Harris A, **Wilson MR**, Topouzis F, Yu F, Kagemann L, Anastasopoulos E, Koskosas A, Pappas F, Coleman A: Aging Increases Areas of Low Capillary Blood Flow in the Peripapillary Retinal Circulation of Normal Individuals. Invest Ophthalmol Vis Sci (Suppl): 359, 2003.
70. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is there a penalty for delayed treatment in ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS). Presented at ARVO, May 4-9, 2003.
71. Varma R, Francis B, Nguyen B, **Wilson MR**, Lai M, Azen S, LALES Group: Prevalence of Open-Angle Glaucoma and Ocular Hypertension in Latinos. Invest Ophthalmol Vis Sci (Suppl): 3173, 2003.
72. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Koskosas A, **Wilson MR**: Systemic Factors Affecting Optic Disc Topographic Heidelberg Retina Tomograph Parameters in the General Population. Invest Ophthalmol Vis Sci (Suppl.): 3381, 2003.
73. Gong G, Kosoko-Lasaki O, Haynatzki GR, **Wilson MR**. The Overall Frequency of Myocilin Mutations Is Higher in the African American General Population. Invest Ophthalmol Vis Sci (Suppl.): 2723, 2004.
74. Topouzis F, Coleman A, Jonescu-Cuypers C, Yu F, Harris A, Mavroudis L, Anastasopoulos E, Kagemann L, Pappas T, **Wilson MR**: Comparison of the Optic Disc Topographic Heidelberg Retina Tomograph (HRT) Parameters Between Subjects with Normal Blood Pressure (BP) and Subjects with Systemic Hypertension. Invest Ophthalmol Vis Sci (Suppl.): 3352, 2004.
75. Pena FY, Lai MY, Francis, BA, Nguyen BB, Deneen J, **Wilson MR**, Azen SP, Varma R. Clinical Characteristics of Latinos with Open-Angle Glaucoma and Ocular Hypertension. Invest Ophthalmol Vis Sci (Suppl.): 4486, 2004.

76. Gong G, Kosoko-Lasaki O, Haynatzki G, Lynch JF, Lynch HT, **Wilson MR**. Familial Aggregation in Genetic Studies of Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci (Suppl.)*: 3809, 2005.
77. Anastasopoulos E, Toupouzis F, **Wilson M**, Harris A, Yu F, Kosokas A, Pappas T, Mavroudis L, Karkamani G, Coleman A. Prevalence of Late Age-Related Maculopathy (AMD) in Greece: Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci (Suppl.)*: 2210, 2006.
78. Toupouzis F, Coleman A, Harris A, Anastasopoulos E, Yu F, Kosokas A, Pappas T, **Wilson M**. Prevalence of Undiagnosed Primary Open Angle Glaucoma and Pseudoexfoliative Glaucoma in Greece: Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci (Suppl.)*: 3423, 2006.
79. Racette L, Boden C, Kleinhandler SL, Girkin CA, Liebmann JM, Zangwill LM, Medeiros FA, Bowd C, Weinreb RN, **Wilson MR**, et al. Differences in Visual Function and Optic Nerve Structure Between Healthy Eyes in Blacks and Whites. *International Glaucoma Review*, Volume 7-3, 2006.
80. Toupouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E, Dimitrakos S, **Wilson MR**. Risk of Sudden Visual Loss Following Filtration Surgery in End-Stage Glaucoma. *International Glaucoma Review*, Volume 7-3, 2006.
81. Anastasopoulos E, Topouzis F, Harris A, **Wilson MR**, Yu F, Koskosas A, Pappas T, Founti P, Coleman AL. Comparison of characteristics of pseudoexfoliative vs non-pseudoexfoliative subjects in a population-based study. Evidence from the Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci (Suppl.)*: 1563, 2007.
82. Topouzis F, **Wilson MR**, Harris A, Anastasopoulos E, Yu F, Pappas T, Koskosas A, Founti P, Coleman AL. Prevalence of primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEXG) by IOP level in a population-based study. Evidence from the Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci (Suppl.)*: 4344, 2007.
83. Topouzis F, Coleman AL, Harris A, Yu F, Anastasopoulos E, Pappas T, Koskosas A, Founti P, **Wilson MR**. Management Patterns of Glaucoma Treatment in the Thessaloniki Eye Study (TES). *Invest Ophthalmol Vis Sci (Suppl.)*: 3604, 2008.
84. Coleman AL, **Wilson MR**, Harris A, Anastasopoulos E, Yu F, Koskosas A, Pappas T, Founti P, Topouzis F. Risk Factors for Open-Angle Glaucoma in the Thessaloniki Eye Study (TES). *Invest Ophthalmol Vis Sci (Suppl.)*: 5450, 2008.
85. Topouzis F, **Wilson MR**, Harris A, Anastasopoulos E, Yu F, Pappas T, Founti P, Koskosas A, Salonikiou A, Coleman AL. Similarities and Differences in Risk Factors for Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma in the Thessaloniki Eye Study. *Invest Ophthalmol Vis Sci (Suppl.)* 2010.

Published Abstracts as Part of Ocular Hypertension Treatment Study Group (Member of Steering/Executive Committee)

86. Wong KF, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automated Forms Processing: Trials, Tribulations and Triumphs. *Controlled Clin Trials* 15:3S, p. 76S, 1994.

87. Gordon MO, Li Z, Schechtman KB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Minimizing Variability and Regression to the Mean in IOP Measurements. *Invest Ophthalmol Vis. Sci* 36:4, S81, 1995.
88. Wong KF, Gordon MO, Achtenberg JF, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic Document Archival for a Data Coordinating Center. *Controlled Clin Trials* 16:3S, p. 38S, 1995.
89. Gordon MO, Schechtman KB, Li Z, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: A Protocol to Minimize Bias and Regression to the Mean in Measurement of Intraocular Pressure. *Controlled Clin Trials* 16:3S, p. 98S, 1995.
90. Gordon MO, Johnson CA, Spurr JO, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group: Pluses and Minuses of Relaxing Fixation Loss Criterion. *Invest Ophthalmol Vis. Sci* 37:3, S507, 1996.
91. Wong K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: An inexpensive electronic system for handling adverse event reports. *Controlled Clin Trials* 17:2S, 1996.
92. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automatic forms processing with Windows 95: Hyperbole? *Controlled Clin Trials* 17:2S, 1996.
93. Wong K, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic systems for handling adverse event reports. *Controlled Clin Trials* 18(3S): 145S, 1997.
94. Bennett GR, Cioffi GA, Dorr D, Gordon MO, Beck A, Fechtner R, Kass M, and the Ocular Hypertension Treatment Study (OHTS) Group: Racial differences in response to glaucoma medications in ocular hypertensive patients. *Invest Ophthalmol Vis. Sci* 38(3): S278, 1997.
95. Gross R, Piltz J, Shin DH, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Contralateral effect of topical beta-blockers on intraocular pressure in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis. Sci* 38(4): S1056, 1997.
96. Dorr D, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH® Software. *Proceedings of the twenty-third Annual SAS Users Group International Conference*: 856-859, 1998.
97. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 39(4): S493, 1998.
98. Gordon MO, Kass MA, Heuer D, Higginbotham E, Parrish R and the Ocular Hypertension Treatment Study (OHTS) Group: Baseline demographics and clinical characteristics of patients enrolled in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 39(4): S878, 1998.
99. Morris PA, Wilder AK, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Site visit strategies to increase collaboration of the clinic, resource centers and coordinating center. *Controlled Clin Trials* 19(3S): 51S, 1998.

100. Dorr DA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: A simple graphical method for displaying multiple dimensions by group over time: and example using the SF-36. *Controlled Clin Trials* 19(3S): 72S, 1998.
101. Fischbach E, Achtenberg J, Clark K, Tourville D, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: (Under) Estimating paper storage requirements for a multicenter clinical trial. *Controlled Clin Trials* 19(3S): 84S, 1998.
102. Bednarski M, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group and the Collaborative Longitudinal Evaluation of Keratoconus Study (CLEK) Groups: A quick and dirty method for delivering SAS® reports via the world wide web. *MWSUG Conference Proceedings*, 405-410, 1998.
103. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group: Delivering coordinating center reports to clinics via the world wide web. *Controlled Clin Trials* 20(2S): 60S, 1999.
104. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Offering continuation education credits at clinic coordinating meeting. *Controlled Clin Trials* 20(2S): 67S, 1999.
105. Morris PA, Wilder AK, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Accessing SAS reports by the central coordinators via the world wide web. *Controlled Clin Trials* 20(2S): 68S, 1999.
106. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Reproducibility of reading of optic disc cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 40(4): S283, 1999.
107. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group: Classification of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 40(4): S69, 1999.
108. Keltner JL, Johnson CA, Cello KE, Quigg JM, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Severity of the types of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 41(4): S84, 2000.
109. Long E, Dunn D, Gordon M, Ocular Hypertension Treatment Study (OHTS) Group. A publications and presentation policy for a multicenter clinical trial. *Control Clin Trials*: 21(2S): 77S, 2000.
110. Randant D, Long E, Gordon M, the Ocular Hypertension Treatment Study (OHTS) Group. Handling forms in a multicenter clinical trial. *Control Clin Trials* 21(2S): 100S, 2000.
111. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA, Ocular Hypertension Study (OHTS) Group. Visual field technician performance in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 42(4): S152, 2001.

112. Brandt JD, Beiser J, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. The relationship of corneal thickness and IOP response to topical β -blocker in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 42(4): S421, 2001.
113. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Improving timeliness of annual IRB approvals. *Control Clin Trials* 22(2S): 79S, 2001.
114. Bednarski MA, Beiser JA, Gordon MA, Morris PA, Wilder AK, and the Ocular Hypertension Study (OHTS) Group. Providing performance reports to clinics via the world wide web. *Control Clin Trials* 22(2S): 80S, 2001.
115. Morris PA, Wilder AK, Bednarski M, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Omnibus clinic tracking report. *Control Clin Trials* 22(2S): 83S, 2001.
116. Bednarski MA, Clark KA, Hornbeck EM, Gordon MO. Dynamic data retrieval using SAS/IntrNet. SAS Users Group International, paper 197, April 14-17, 2002.
117. Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Viewing case report forms on the web without scanning data. *Control Clin Trials* 23(2S): 40S, 2002.
118. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Is there a penalty for delayed treatment in ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study. Presented at ARVO, May 4-9, 2003.
119. Achtenberg JF, Hornbeck EM, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Enhanced documentation of case report forms. *Control Clin Trials* 24(3S): 180S, 2003.
120. Bednarski MA, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study Group. Tracking and reporting multi-stage processes in a clinical trial. *Control Clin Trials* 24(S): 187S, 2003.
121. Kymes SM, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Economic evaluation in randomized clinical trials - a promise half met? *Control Clin Trials* 24(3S): 187S, 2003.
122. Morris PA, Wilder AK, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. Encouraging participation after protocol change. *Control Clin Trials* 24(S): 214S, 2003.
123. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Types of visual field abnormalities that subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS). *Invest Ophthalmol Vis Sci* 45: E-Abstract 2134, 2004.
124. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. A predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). *Invest Ophthalmol Vis Sci* 45: E-Abstract 955, 2004.

125. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Detection and predictive value of optic disc hemorrhages in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 45: E-Abstract 940, 2004.
126. Beiser JA, Hornbeck E, Morrison D, Gordon MO, Goldberg J. De-identification of shared datasets. Clinical Trials 1(1S): 274, 2004.
127. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 2449, 2004.
128. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW and the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality control in the Ocular Hypertension Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 46: E-Abstract 3738, 2004.
129. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Is there an association of topical ocular hypotensive medication with lens opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 2448, 2004.
130. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Test-retest reproducibility of determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 46: E-Abstract 3630, 2004.
131. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) CSLO Ancillary Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthalmol Vis Sci 46: E-Abstract 3631, 2004.
132. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon MO, Beck RW and the Ocular Hypertension Treatment Study (OHTS) Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT). Invest Ophthalmol Vis Sci: E-Abstract 3394, 2006.
133. Brandt JD, Beiser JA, Gordon MO, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Time Dependent Changes in Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci: E-Abstract 4422, 2006.
134. Morris PA, Roediger T, Achtenberg J, Bednarski M, Clark K, Hornbeck B, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Certification training, and support of a web-based data entry system. Clinical Trials: 3:191-247, 2006.
135. Clark KA, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group. Integrating adverse event data into a web-based data management. Clinical Trials: 3:191-247, 2006.

136. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. A Comparison of Full Threshold and Swedish Interactive Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci: E-Abstract 1643, 2007.
137. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses of Visual Field Progression in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci: E-Abstract 4447, 2007.
138. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA, Gordon MO, and Ocular Hypertension Treatment Study Group. The Predictive Accuracy of the One-Eyed Trial in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci: E-Abstract 5555, 2007.
139. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Treatment Study Group. Phased transition from traditional data entry to a web-based system. Presented at SCT, May 21-24, 2007.
140. Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is a history of diabetes mellitus (DM) protective against developing primary open-angle glaucoma (POAG)? Presented at the American Glaucoma Society, March 7, 2008.
141. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Application of Brusini's Glaucoma Staging System 2 (GSS 2) to glaucomatous visual fields in the Ocular Hypertension Treatment Study. Presented at ARVO, April 27, 2008.
142. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Intraocular pressure variability in observation participants in the Ocular Hypertension Treatment Study. Presented at ARVO, April 28, 2008.
143. Kymes SM, Kass MA, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group. The 20-year incidence of primary open-angle glaucoma among people with ocular hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.
144. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Retinal vein occlusions (RVO) in the Ocular Hypertension Treatment Study. Presented at ARVO, May 1, 2008.
145. Long EF, Dunn D, Gordon MO, the Ocular Hypertension Treatment Study Group. Close-out manual of procedures for a long-term clinical trial. Presented at the Society for Clinical Trials. May 19, 2008.
146. Gordon MO, Sarli C, Long EF, LaRue C, the Ocular Hypertension Treatment Study Group. Assessing the impact of research. Presented at the Society for Clinical Trials, May 20, 2008.
147. Gordon MO, Heuer DK, Higginbotham EJ, Parrish RK, Morris PA, Dunn DA, Wilson BS, Kass MA, the Ocular Hypertension Treatment Study Group. Impact of attributing cause of abnormality to POAG on endpoint rate and statistical power in the OHTS. Presented at ARVO, May 2, 2010.